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Molecular Approaches to Targeting Oncogenic KRAS and Ferroptosis  
Huizhong Feng 
 
Both small molecules and antibodies are powerful tools for research in biological 
mechanisms and therapeutics. The discovery of such molecules involves two 
opposite starting points: one being specific targets and the other being 
phenotypic screens. The first part of this thesis focuses on drug development 
starting with a specific target. The second part of this thesis focuses on 
identification of ferroptosis biomarkers by phenotypic screen.  
The specific target highlighted in the first part of this thesis is KRAS 
(Kirsten rat sarcoma viral oncogene homolog), the most commonly mutated 
oncogene in human pancreatic cancers, colorectal cancers, and lung cancers. 
The high prevalence of KRAS mutations and its prominent role in many cancers 
make it a potentially attractive drug target; however, it has been difficult to 
design small molecule inhibitors of mutant K-Ras proteins. Here, we identified a 
putative small molecule binding site on K-RasG12D, which we have termed the 
P110 site (due to its adjacency to proline 110), using computational analyses of 
the protein structure. We then confirmed that one compound, named K-Ras 
Allosteric Ligand KAL-21404358, might bind to the P110 site of K-RasG12D using 
a combination of computational and biochemical approaches.  
The phenotypic screen used in the second part of this thesis focus on the 
process of ferroptosis, a form of regulated cell death process driven by the iron-
 iv 
dependent accumulation of polyunsaturated-fatty-acid-containing phospholipids 
(PUFA-PLs). Currently, there is no way to selectively stain ferroptotic cells in 
tissue sections to characterize relevant models and diseases. To circumvent this 
problem, we immunized mice with membranes from diffuse large B Cell 
lymphoma (DLBCL) cells treated with piperazine erastin (PE), and screened 
~4,750 of the generated monoclonal antibodies by phenotypic screen. We found 
that the 3F3 anti-Ferroptotic Membrane Antibody, termed 3F3 FMA, was 
effective as a ferroptotic staining reagent. The antigen of 3F3 FMA was then 
identified as the transferrin receptor protein 1 (TfR1), which imports iron from the 
extracellular environment into cells. We further compared 3F3 FMA with other 
potential ferroptotic staining reagents. TfR1 3B8 2A1 along with the MDA 1F83 
antibody allow for the first time the detection of cells undergoing ferroptosis in 
human tissue sections. 
In summary, these two projects illustrate how molecular screening and 
design starting from either a specific target or a phenotype screen aid in drug and 
biomarker development.
 i 
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Chapter 1 Introduction 
1.1 Molecular approaches to probe biological mechanisms  
1.1.1 Drug discovery strategies 
Four strategies are predominantly used to identify potential drug candidates. 
They are phenotypic drug development (PDD), target-based drug development 
(TDD), modification of natural substances and biologic-based approaches. 
Traditionally, the process most often-used to identify potential candidates is PDD. 
Between 1999 and 2008, 75 agents were approved by the US Food and Drug 
Administration as first-in-class drugs with new molecular mechanism of action 
(MMOA)1. Out of the 75 agents, 28 were discovered by PDD, 17 were identified 
via TDD, 5 were modified natural substances and 25 were biologics2. But current 
drug therapy is based on fewer than 500 molecular targets, at least 10 times less 
than the predicted 5,000 and 10,000 potential drug targets3. We urgently need 
more molecular targets to develop new and better therapies.  
  
TDD has become an increasingly effective as an area of drug discovery, with the 
successes of imatinib (Gleevec) (target BCR-ABL) and gefitinib (Iressa) (target 
EGFR). The transition from PDD to TDD is being facilitated by the advances in 
molecular biology, new technologies and combinatorial chemistry. Basic 
molecular biology elucidates the biological mechanisms behind disease 
processes at the molecular/genetic level, and helps determine new drug targets 
for drug discovery, while new technology facilitates drug discovery via high-
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throughput screening (HTS) and helps validate hits. Computational technology 
helps increase the speed and decrease the labor required to do screens, and 
advances in new biophysical techniques such as surface plasmon resonance 
(SPR) and microscale thermophoresis (MST) show reliable results and require 
less protein. The availability of combinatorial chemistry libraries gives chemists 
more flexibility to design compounds with higher affinity and efficacy. In addition, 
structure-activity relationship (SAR) research is an important step for drug 
discovery following the identification of an initial hit.  
 
TDD offers a rational, measurable process from gene to clinic. It takes advantage 
of molecular genetics, chemistry and informatics knowledge to provide criteria for 
choosing patient populations and setting doses2. The disadvantage is that using 
TDD risks not finding any hits relevant to the disease. Traditional PDD is more 
likely to result in drug candidates that can be translated into therapies, and it 
does not require prior knowledge of a molecular target. However, it is risky to 
begin clinical trials without the identification of the target. With PDD, the follow-up 
optimization of initial hits is also limited. Therefore, the identification of the 
molecular target is of equal importance in both TDD and PDD. Regardless of 
whether drug discovery starts with a specific target or with a phenotype, rational 




1.1.2 Biomarker discovery strategies 
A biomarker is a measurable indicator of a specific biological state4. Biomarkers 
are needed in scientific research to improve diagnosis and monitor activity in 
therapeutics. Biomarkers can take different forms, including DNA, mRNA, 
antigen, and enzymes5. However, protein biomarkers represent the most 
common type and are widely used both in research and clinical settings6.  
 
Two strategies are used to discover new biomarkers: mass spectrometry (MS)-
based detection and fluorescence-based methods. With the advances of 
electrospray ionization (ESI)7 and matrix-assisted laser desorption/ionization 
(MALDI)-MS8, MS has become a powerful tool in identifying protein biomarkers. 
The MS-based biomarker discovery strategy includes six steps: sample collection, 
fractionation, mass spectral analysis, data analysis and biological filtering 
(bioinformatics), and ultimately validation5. The samples come from a specific 
population such as blood, cerebrospinal fluid or urine. First, they are fractionated 
and proteolytically digested into peptides that are used in MS for protein 
identification and quantification. The identified proteins are further studied 
utilizing the enzyme-linked immunosorbent assay (ELISA) or fluorescence 
spectroscopy. Finally, validation is focused on specificity and sensitivity, which 
are the two main criteria for biomarker assessment.  
 
In comparison, fluorescence-based detection is more similar to a phenotypic 
screen. It starts with a library of antibodies and uses fluorescence change as a 
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criterion. Flow cytometry is a quick and straightforward way to sort cells with 
different fluorescence intensities. However, this application is limited and it 
cannot be expanded to in situ staining of tissue sections which are more related 
to human diseases and pathologies. Microscopy-based fluorescence detection, 
however, can make up for this disadvantage by immunostaining both cell culture 
and tissue section samples. Using a confocal microscope, we can identify the 
distribution of the biomarker and its effects on cell shape and polarization. By co-
staining with organelle markers, we can localize the biomarker. Fluorescence-
based methods also involve the application of MS—when a potential candidate is 
discovered, MS is used for protein identification and quantification.  
 
1.2 Ras family 
1.2.1 Brief introduction of Ras 
One potentially important drug target is Ras proteins. Ras proteins belong to the 
small GTPase family and are involved in transmitting growth, survival, and 
proliferation signals within cells. As a GTPase, Ras cycles between a GTP-bound 
state and a GDP-bound inactive state, the transition of which is regulated by 
guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins 
(GAPs)9, 10. Two regions of Ras proteins, switch I (residues 30–40) and switch II 
(residues 60–76), undergo substantial conformational changes and form 
effector–protein interaction surfaces upon GTP binding11. In the GTP-bound 
active state, Ras interacts with effector proteins and activates downstream 
cellular signal transduction pathways, including the RAF-MEK-ERK, PI3K-AKT-
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mTOR, and RalGDS pathways12. Oncogenic mutants of Ras are locked in an 
active signaling state: the constitutive activation of Ras downstream signaling 
results in sustained proliferation, metabolic reprogramming, inhibition of 
apoptosis, and other hallmarks of cancer13. 
 
The prevalence of Ras mutations in cancers is high: 97.7% of pancreatic ductal 
adenocarcinoma, 52.2% of colon and rectal carcinoma, 42.6% of multiple 
myeloma and 32.2% of lung adenocarcinoma. However, currently, there are no 
Ras inhibitors in clinical use. The imbalance of significance in cancers and lack of 
inhibitors makes Ras an attractive and challenging target for drug development.  
 
1.2.2 Ras superfamily  
The Ras superfamily of small guanosine triphosphatases is composed of over 
150 human members which share conserved G box GDP/GTP-binding motif 
elements and function as GDP/GTP-regulated switches. The Ras superfamily 
has been universally divided into five major categories: Ras family, Rho family, 
Rab family, Ran family and Arf family14. Ras proteins are founding members of 
this superfamily. They were initially identified as oncogenic viral genes 
transduced from the rodent genome15.  The discovery of Harvey murine sarcoma 
virus in 196416 and Kirsten murine sarcoma virus in 196717 opened the door to 
intensive research on Ras. The identification of mutationally activated human 
RAS genes in human cancer cell lines in 1982 marked the official discovery of 
Ras for the first time18.  
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Ras’s ability to cause rat sarcomas became the basis of their current gene name 
RAS and the names of the discoverers Harvey and Kirsten became the prefix 
HRAS and KRAS19. In 1983, a third transforming human RAS gene was 
discovered in neuroblastoma-derived DNA, therefore named NRAS20, 21. 
Together KRAS, HRAS, and NRAS comprise the most common RAS gene family. 
Other proteins belonging to the Ras superfamily include R-Ras, Ral, Rap and 
Rheb. 
 
The Rho (Ras homologous) family is a group of key regulators of actin 
reorganization22, including 20 members of which RhoA, Rac1 and Cdc42 are well 
studied. Proteins in the Rab (Ras-like proteins in brain) family function in 
intracellular vesicular transport between different organelles23. This family 
includes 61 members and accounts for the largest branch of the Ras superfamily. 
The fourth family is Ran (Ras-like nuclear) proteins. As its names indicates, it is 
involved in the shuttling of proteins and RNA between the nucleus and 
cytoplasm24. The switching of function of Ran proteins requires the spatial 
gradient of the GTP-bound form of Ran and depends on the gradient of Ran-
activating GEFs in the nucleus and GAPs in the cytoplasm14. The fifth is the Arf 
(ADP-ribosylation factor) family. It also functions in intracellular vesicular 
transport in the exocytic and endocytic pathways25.  
In this paper, I will focus on Ras proteins, especially K-Ras protein because of its 
significance in cancers which will be discussed in detail in 1.2.5.  
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1.2.3 Ras structure and function 
Three human Ras genes KRAS, HRAS and NRAS encode four proteins: the 
splice variants K-Ras4A and K-Ras4B, H-Ras and N-Ras. We can divide their 
sequence into two main parts: the G domain (also called catalytic domain, 
residue 1-166) and the hypervariable region (HVR). The four proteins share 90% 
sequence identity in the catalytic domain but contain significant differences in the 
HVR26. The primary and secondary structures of K-Ras are shown in Figure 1.1. 
 
 
Figure 1.1 Schematic diagram of primary and secondary structures of K-Ras 
 
The G domain consists six β-strands, five α -helices and ten connecting loops. 
 
There are three functional domains: P-loop between β1 and α1, Switch I between 
α1 and β2 and Switch II between β3 and α2. P-loop (residue 10-17) is 
                     10                         20                      30                      40                      50
MTEYKLVVVG  AGGVGKSALT  IQLIQNHFVD  EYDPTIEDSY  RKQVVIDGET 
                     
                     60                         70                       80                     90                    100
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responsible for phosphate binding. It endows Ras proteins the function of 
switching between the GDP-bound inactive state and the GTP-bound active 
state27. Switch I (residue 30-40) and switch II (residue 60-76) also interact with γ-
phosphate and undergo conformational changes upon binding with GTP. 
Specifically, G13 from P-loop, Y32 from switch I and Q61 from switch II form 
direct H-bonds with GTP.  
 
The hypervariable region contains CAAX motif which is the recognition site for 
farnesyltransferase and prenyltransferase. C represents cysteine. A is isoleucine, 
leucine or valine. X represents serine or methionine28. A farnesyl or 
geranylgeranyl lipid is linked to the CAAX cysteine via thioether by 
farnesyltransferase or prenyltransferase. Then -AAX residues are cleaved, 
leading to the modification of new C terminal cysteine to be methylesterified. N-
Ras and H-Ras undergo palmitoylation in the HVR domain upstream of CAAX as 
well29. Together, these post-translational modifications generate a hydrophobic 
area on an otherwise hydrophilic molecule, responsible for plasma membrane 
anchoring and trafficking of newly synthesized Ras proteins30. The localization to 
the plasma membrane is a prerequisite for Ras signaling and biological activity. 
 
1.2.4 Ras signaling 
RAS signaling works in two directions: upstream and downstream (Figure 1.2). 
Upstream signaling involves guanine nucleotide exchange factors (GEFs) and 
GTPase activating proteins (GAPs). GEFs help replace bound GDP to GTP and 
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GAPs accelerate the rate of GTP hydrolysis. The best characterized GEFs are 
SOS1 and SOS2. The activation of receptor tyrosine kinases leads to the binding 
with adaptor proteins, such as growth-factor-receptor-bound protein 2 (GRB2) via 
SHC protein. The activation of GRB2 recruits SOS to the plasma membrane 
where Ras is also localized as a result of farnesylation31. The C-terminal domain 
(catalytic domain, residues 752-1044) interacts with Ras in the area containing P-
loop and surround segments (strand β1 and helix α1), switch I and switch II32. 
The interface is hydrophilic and extensive with 3,600 Å2 of surface area buried in 
the complex32. Though Ras can hydrolyze GTP on its own, the rate is inefficient. 
By interacting with GAPs, Ras has an improved rate of GTP hydrolysis. 
P120GAP and neurofibromin are two well characterized GAPs33. Arg789 of 
p120GAP forms van der Waals contact with G12 and Q61 of Ras33. Therefore, 
the mutation of G12 and Q61 disables GAP-catalyzed GTP hydrolysis and 
renders Ras constitutively active. 
 
There are two states (state 1 and state 2) of GTP-bound Ras34. State 1 favors 
nucleotide exchange but inactivates effector proteins and following downstream 
signaling while state 2 activates effector binding and GTP hydrolysis35, 36. 
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Figure 1.2 Schematic overview of Ras signaling. 
 
The downstream signaling of Ras includes four main pathways. The first is the 
RAF-MEK-ERK pathway. The protein serine/threonine kinase RAF is the most 
intensively-studied Ras effector31. Three Raf proteins (c-Raf1, b-Raf and a-Raf) 
have been identified as binding to GTP-bound Ras and being relocated to the 
plasma membrane37. Activated Raf phosphorylates and activates mitogen-
activated protein kinase kinases 1 and 2 (Mek1/2), which then phosphorylate and 
activate extracellular signal-regulated kinases 1 and 2 (Erk1/2), which are also 
known as mitogen-activated protein kinases (MAPKs). Erk1/2 can activate a 
series of cytosolic and nuclear proteins including transcriptional factors ELK1, 
PLA2, RSK and c-JUN. The activation of these transcriptional regulators prompts 
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cells to progress into G1 phase of the cell cycle, thereby leading to cell 
proliferation38.  
 
The second downstream signaling is the PI3K-PDK1-AKT pathway. Ras directly 
binds to PI3K (phosphatidylinositol 3-kinases) which is capable of 
phosphorylating phosphatidyl inositol bisphosphate [PtdIns(4,5)P2] to generate 
phosphatidyl inositol trisphosphate [PtdIns(3,4,5)P3], leading to the activation of 
kinases PDK1 (3-phosphoinositide-dependent protein kinase-1) and AKT. AKT is 
involved in anti-apoptotic processes and is important for cell survival39.  
 
The third well-established pathway is through Ras-related Ral proteins which 
include three major members: RALGDS (Ral guanine nucleotide dissociation 
stimulator), RALGDS-like gene (RGL/RSB2) and RGL2/RLF. The activation of 
these proteins stimulate Ral, leading to the activation of phospholipase D1 and 
RALBP1 (Cdc42/Rac-Gap-Ral binding protein 1) to promote cell-cycle arrest31.  
 
The last downstream pathway is through phospholipase Cε (PLCε)40. In addition 
to conserved PLC domains, PLCε has a GEF domain and two Ras binding 
domains, which enables its direct interaction with Ras. PLCε then hydrolyzes 
PtdIns(4,5)P2 to generate Ins(1,4,5)P3, leading to the regulation of many cellular 
proteins related to this inositol lipid41. 
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1.2.5 Ras mutations in cancers 
The frequency and distribution of RAS gene mutations in cancers are not uniform 
among the three Ras family members KRAS, HRAS, and NRAS19 (Figure 1.3). 
KRAS is the most frequently mutated gene and is altered in 86% of RAS-driven 
cancers, followed by 11% for NRAS and 3% for HRAS42. G12, G13, and Q61 are 
three major spot point mutations which account for 98% of all oncogenic Ras 
mutations. G12 mutation is mostly found for KRAS (83%), Q61 mutation is mostly 
found in NRAS (62%). But in HRAS, the three mutations are equally distributed 
(35% for G12, 34% for Q16 and 27% for G13)43. For G12 mutation, G12D is the 
most prevalent one (36%), followed by G12V (23%) and G12C (14%)44. That is 
the first of two reasons we chose K-RasG12D as the drug discovery target. 
 































Moreover, KRAS G12 is the predominant mutation in pancreatic ductal 
adenocarcinoma (PDAC), lung adenocarcinoma (LAC) and colon and rectal 
carcinoma (CRC). Among these mutations, G12D mutation accounts for 51% in 
PDAC and 45% in CRC while G12C accounts for 44% in LAC43. PDAC has been 
acknowledged as one of the most aggressive and lethal cancers with few 
available treatments45. Though pancreatic cancer was the 12th most common 
type of cancer in the US in 2014, it was the 4th most common cause of cancer-
related death with the overall 5-year survival rate at 7.2%46. Complete surgical 
removal of the tumor is the only chance for cure, however only 10-20% of 
patients are surgically curable47. The lethality of PDAC makes the drug discovery 
for KRAS mutations, especially KRAS G12D mutation in high demand. That is 
the second reason why we chose K-RasG12D as the target. 
 
1.2.6 Drug discovery for oncogenic Ras 
Ras has been considered an undruggable target due to the lack of deep and 
hydrophobic pockets, high binding affinity with GTP and tight protein-protein 
interactions with its effectors. Despite these difficulties, direct inhibitors of K-Ras 
have been long explored by researchers all over the world. Here I categorize 
them into five major strategies (Figure 1.4). The first is to target G12C-specific K-
Ras mutants with covalent, cysteine-reactive electrophilic inhibitors. In addition to 
the covalent bond, an expandable pocket proximal to the mutated cysteine 12 
and Switch II also helps lock K-RasG12C in the inactive state. ARS-853, ARS-1620, 
MRTX849 and 4-AM quinazoline inhibitors are good examples of this category48-
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50. ARS-1620 not only had high affinity and selectivity in vitro, but also showed 
rapid and sustained tumor regression activity in vivo50. To note, the first K-
RasG12C inhibitor entering clinical trial, AMG510 from Amgen, belongs to this 
category. AMG510’s first clinical result was recently announced to show positive 
anti-tumor activity. MRTX849 from Mirati therapeutics also entered the clinical 
trial in January 201951. It was identified through intensive structure-based drug 
screening with more than 150 unique co-crystal structures. It targets K-RasG12C 
with noncovalent binding. 
 
Figure 1.4 Five strategies to design Ras inhibitors.  
 
* labels the inhibitors in clinical trials. 
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The second strategy is to block Ras–effector interactions by developing small 
molecule and peptide inhibitors. Kobe0065 and its analog Kebe2602 were 
discovered to inhibit the interaction between GTP-bound H-Ras and c-Raf-1 both 
in vivo and in vitro. Kobe2601 binds to the Switch II region of H-Ras in close 
proximity to the side chains of Leu56, Met67, Gln70, Tyr71, and Thr7452. Abd-7 
was discovered to bind to the same pocket and inhibits Ras PPIs and 
downstream signaling pathways53. AbdCell-permeable bicyclic peptides against 
K-RasG12V were identified to block Ras-effector interactions in vitro and induce 
apoptosis of the cancer cells54. 3144 was designed to bind to the Switch I region 
near D38 and Y32 as well as A59 between the Switch I and Switch II55. 3144 also 
displayed anti-tumor activity in xenograft mouse cancer models. 
Pyrazolopyrimidine-based inhibitors were discovered to bind to K5, L6, V7, E37, 
D38, S39 and Y71 at sub-micromolar KD and interrupt K-Ras/Raf interactions and 
Ras downstream signaling56. 
 
The third strategy is to interrupt nucleotide exchange, including the K-Ras–GEF 
interaction and modification of the GTP binding site. DCAI was discovered to 
block the interactions between SOS and K-Ras by binding to the region close to 
Switch I and II domain57. A series of compounds were identified to bind directly to 
K-Ras between the Switch I and II and inhibit SOS-mediated nucleotide 
exchange58. These two kinds of inhibitors shared the same binding pocket with 
Kobe2601 and Abd-7. YZ0711 was able to covalently bind to engineered K-Ras* 
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at the modified nucleotide-binding site, thereby inhibiting Ras-Raf-Mek-Erk and 
Ras-PI3K-Akt signaling pathways59. BAY-293 was recently designed to bind into 
a surface pocket on SOS1 adjacent to the K-Ras binding site and selectively 
inhibit the K-Ras-SOS1 interaction with an IC50 at 21 nM60.  
 
The fourth category encompasses allosteric regulatory inhibitors, which is an 
emerging area for design of Ras inhibitors. NS1, a monobody, is able to bind to 
H-Ras and K-Ras but not N-Ras at the α4-β6-α5 region and inhibit Ras 
dimerization and nanoclustering, resulting in the inhibition of Ras-Raf-Mek-Erk 
signaling61. Recently, DARPins K13 and K19, two ankyrin repeat proteins, were 
reported to bind around K-Ras-specific residue histidine 95 at the α3-loop7-α462. 
K13 and K19 are able to inhibit K-Ras nucleotide exchange, K-Ras/effector 
interactions and dimerization at the plasma membrane62. Zn2+ cyclen was found 
to have two distinct binding sites. One was close to the γ-phosphate of the 
nucleotide and the other is the negatively charged loop L7 in proximity to Asp105, 
Ser106, Asp107, Asp108, Val109, Met111 and C-terminal residues Glu162, 
Gln165, and His16663. 
 
The fifth strategy is to target Ras membrane localization. The most successful 
inhibitor of this category is Salirasib. Salirasib, a Ras farnesylcysteine mimetic, 
can selectively interrupt the association of active Ras with the plasma membrane 
by competing with Ras for binding to Ras-escort proteins64. Phase I clinical trial 
of Salirasib in US and Japan showed positive results with safety and well 
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toleration65, 66. There are also other indirect inhibitors to disrupt Ras membrane 
localization. Tipifarnib and lonafarnib are farnesyltransferase inhibitors (FTIs) and 
were tested in phase III clinical trials67. However, FTIs showed no anti-tumor 
activity for KRAS-driven and NRAS-driven cancer because they have alternative 
geranylgeranyl transferase mediated pathway68. Thus, inhibition of RCE1 and 
ICMT following the farnesyltransferase/geranylgeranyl transferase activity is also 
of interest. Phosphodiesterase-δ (PDEδ) is another target because PDEδ is 
involved in the translocation of Ras to the plasma membrane. The inhibition of 
PDEδ retains Ras on endomembranes, thus maintaining its inactive state69, 70.  
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1.3 Ferroptosis1 
1.3.1 Cell death and ferroptosis 
The fundamental building block of life is the cell, the smallest living unit within 
multicellular organisms. Cells, like the organisms they constitute, live and die. 
According to the recommendations of the Nomenclature Committee on Cell 
Death (NCCD), cell death can be accidental or regulated71. Accidental cell death 
occurs when cells experience overwhelming physical, chemical, or mechanical 
insults; such accidental cell death cannot be modulated by molecularly targeted 
interventions. In contrast, regulated cell death can be modulated 
pharmacologically and genetically, as it is controlled by molecular mechanisms. 
The NCCD defines programmed cell death to be a subset of regulated cell death 
that occurs in normal physiological contexts71. Caspase-dependent apoptosis is a 
well-known form of regulated, programmed cell death. Ferroptosis is a recently 
described form of cell death that is regulated72, according to the NCCD definition, 
as it can be enhanced and suppressed by specific genetic and pharmacological 
interventions. Ferroptosis is characterized by loss of activity of glutathione 
peroxidase 4 (GPX4), resulting in overwhelming accumulation of lethal lipid 
peroxides73. 
 
                                            
1 Portions of this chapter are adapted from a published manuscript: Feng H, Stockwell BR (2018) 




Ferroptosis was originally coined as a term for the unique form of cell death 
initiated by the small molecules erastin and RAS-selective lethal 3 (RSL3)73 and 
is now defined as a form of cell death that involves accumulation of lipid 
peroxides and that is suppressed by iron chelators and lipophilic antioxidants72 
(Figure 1.5). Other compounds that induce cytosolic or mitochondrial reactive 
oxygen species (ROS) do not induce ferroptosis73, 74; thus, general ROS 
production is not related to ferroptosis. In contrast, ferroptosis is tightly linked to 
lipid peroxidation and can be thought of as death by lipid peroxidation. An open 
question is whether any type of lethal lipid peroxidation is classified as ferroptosis 
or whether only certain types of lethal lipid peroxidation should be termed 
ferroptosis. Since the current definition of ferroptosis is a cell death process 
involving lipid peroxidation that is suppressed by both iron chelators and lipophilic 
antioxidants, any lethal iron-dependent lipid peroxidation would be classified as 
ferroptosis. However, just as elucidation of the mechanisms driving apoptosis 
has revealed different pathways leading to a similar endpoint, such as the 
intrinsic and extrinsic apoptotic pathways, it may be that ferroptosis can be 
initiated and executed by distinct pathways involving different types of lethal iron-




Figure 1.5 Schematic overview of ferroptosis 
 
Summary of ferroptosis mechanisms and signaling pathway. Ferroptosis 
inducers/sensitizers are colored red. Ferroptosis inhibitors are colored green. 
2,2-BP, 2,2-bipyridyl; ACSL4, acyl-CoA synthetase long chain family member 4; 
ALOX, arachidonate lipoxygenase; BHT, butylated hydroxytoluene; CoQ10, 
coenzyme Q10; CPX, ciclopirox olamine; DFO, deferoxamine; D-PUFA, 
deuterated polyunsaturated fatty acids; Fer-1, ferrostatin-1; FIN56, ferroptosis 
inducer 56; FINO2, ferroptosis inducer endoperoxide; GPX4, glutathione 
peroxidase 4; GSSG, glutathione disulfide; HMG-CoA, β-hydroxy β-
methylglutaryl-CoA; IKE, imidazole ketone erastin; LPCAT3, 
lysophosphatidylcholine acyltransferase 3; PL-PUFA (PE), polyunsaturated-fatty-
acid-containing phospholipids; PL-PUFA(PE)-OOH, polyunsaturated-fatty-acid-
containing-phospholipid hydroperoxides; PUFA, polyunsaturated fatty acid; ROS, 




1.3.2 Modulators of ferroptosis and their mechanisms 
Four ways of initiating ferroptosis have been discovered (Table 1.1). Class 1 
ferroptosis inducers act by starving cells of the amino acid cysteine. Such 
compounds act by inhibiting system xc−, a transmembrane cystine-glutamate 
antiporter, which imports cystine (the oxidized, disulfide form of cysteine) into 
cells. When this process is blocked, cysteine is depleted from these cells.  
Cysteine has a number of functions in cells—most importantly, in the context of 
ferroptosis, as a building block for the biosynthesis of glutathione (GSH). GSH is 
a cofactor and substrate for GPX4 and is required for the lipid repair function of 
this enzyme. Depletion of GSH through cysteine starvation leads to loss of GPX4 
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Erastin and its more potent analogs imidazole ketone erastin (IKE) and 
piperazine erastin (PE), as well as the FDA-approved drugs sulfasalazine and 
sorafenib, are small molecule class 1 ferroptosis inducers. In addition, high 
extracellular concentrations of the amino acid neurotransmitter glutamate can act 
as a class 1 ferroptosis inducer. All of these are suitable for use in vitro, although, 
as sorafenib and glutamate also activate other nonferroptotic mechanisms, they 
must be used with care as chemical probes of ferroptosis. Erastin has low 
solubility and poor metabolic stability and pharmacokinetics, preventing its use in 
vivo. Likewise, sulfasalazine has low metabolic stability and low potency, 
preventing its reliable use in vivo. However, sorafenib, IKE, and PE are suitable 
for in vivo use, as they have high potency, sufficient metabolic stability, and 
acceptable pharmacokinetic profiles. 
 
Class 2 ferroptosis inducers act through direct inhibition of GPX4. RSL3 (also 
known as [1S,3R]-RSL3 to indicate the stereochemical configuration) and a 
number of other reported compounds75 covalently interact with the nucleophilic 
active-site selenocysteine of GPX4 and inhibit its enzymatic activity, resulting in 
loss of its lipid repair function, accumulation of lethal lipid peroxides, and 
consequent cell death76. RSL3 is primarily suitable for in vitro use as a potent 
and selective inhibitor of GPX4; its inactive stereoisomer (1R, 3R)-RSL3 is a 
useful inactive negative control compound. Unfortunately, none of the class 2 
ferroptosis inducers are suitable for in vivo use, due to low solubility and difficulty 
characterizing their pharmacokinetics.  
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Class 3 ferroptosis inducers, which include the compounds ferroptosis inducer 56 
(FIN56) and caspase-independent lethal 56 (CIL56), act by depleting GPX4 
protein from cells and simultaneously causing depletion of mevalonate-derived 
coenzyme Q10 (CoQ10), which functions as an endogenous lipophilic antioxidant 
in addition to its well-known function in the mitochondrial electron transport 
chain77. CIL56 also activates a distinct necrotic cell death mechanism, whereas 
FIN56 is a specific inducer of ferroptosis; thus, FIN56 is the more specific 
chemical probe for in vitro use. Neither compound has been used in vivo. 
 
The only class 4 ferroptosis inducer currently known is ferroptosis inducer 
endoperoxide (FINO2), which acts by oxidizing iron, indirectly inactivating GPX4, 
and further driving lipid peroxidation78, 79. This compound is suitable for use in 
vitro and has not been evaluated in vivo, although its moderate potency suggests 
it might not be effective in vivo. A recent report suggested that non-thermal 
plasma might be able to similarly redox cycle iron and perhaps induce ferroptosis 
through this class 4 mechanism80. 
 
Blocking ferroptosis may be useful in treating some degenerative diseases. A 
number of ferroptosis inhibitors that could be used for such purposes have been 
reported (Table 1.2). The first two types of ferroptosis inhibitors identified, as 
noted above, were iron chelators—such as deferoxamine and ciclopirox—and 
lipophilic antioxidants—such as α-tocopherol (a component of vitamin E), 
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butylated hydroxytoluene (BHT), ferrostatin-1 (Fer-1), and liproxstatin-1. Iron 
chelators prevent the initiation of lipid peroxidation by inhibiting lipoxygenases 
(LOXs) and the propagation of lipid peroxidation by suppressing Fenton 
chemistry. Deferoxamine and ciclopirox are suitable for in vivo use; both are 
drugs approved for human use. Lipophilic antioxidants likely exert their effects 
through a radical trapping mechanism to suppress lipid peroxidation81, 82. In 
addition, other ferroptosis inhibitors have been identified, including deuterated 
polyunsaturated fatty acids (D-PUFAs), inhibitors of acyl-CoA synthetase long 
chain family member 4 (ACSL4), glutaminolysis inhibitors, LOX inhibitors, 
cycloheximide, beta-mercaptoethanol, dopamine, selenium, and 











































































Others: glutaminolysis inhibitors, cycloheximide, beta-mercaptoethanol, dopamine, 
selenium, vildagliptin. 
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1.3.3 Cellular pathways involved in ferroptosis 
Lipid metabolism and iron metabolism are vital to ferroptosis and will be 
discussed in detail in chapter 1.4. Here, I will discuss several other cellular 
pathways also involved in ferroptosis. 
 
Glutamate, glutamine and glutaminolysis 
Glutamate is pumped out of cells in exchange for cystine in a 1:1 ratio by system 
xc-. Therefore, high extracellular concentrations of glutamate inhibit the function 
of system xc- , leading to the induction of ferroptosis73. Glutamine degradation via 
glutaminolysis is required for ferroptosis. It has been found that in the absence of 
glutamine or when glutaminolysis is inhibited, cystine starvation fails to induce 
ferroptosis83. Glutaminase 2 (GLS2), which converts glutamine into glutamate, is 
also required for ferroptosis83. 
 
Cysteine: Transsulfuration pathway 
The transsulfuration pathway involves the generation of cysteine from methionine. 
Therefore, cells undergoing the transsulfuration pathway are able to bypass the 
import of cystine via system xc-. The knockdown of cysteinyl-tRNA synthetase 
(CARS) leads to the upregulation of the transsulfuration pathway, resulting in the 






The mevalonate pathway starts with acetyl-CoA and ends with the production of 
two five-carbon building blocks named IPP (isopentenyl pyrophosphate) and 
DMAPP (dimethylallyl pyrophosphate)85. IPP and DMAPP are used to generate 
isoprenoids including cholesterol, heme, vitamin K, coenzyme Q10, and all 
steroid hormones86. Ferroptosis connects to the mevalonate pathway via two 
products, isopentenyl pyrophosphate and coenzyme Q10. GPX4 contains one 
selenocysteine at its active site. The translation of selenocysteine requires the 
special selenocysteine tRNA [tRNA(Sec)] whose maturation process needs the 
lipid modification by tRNA isopentenyl transferase87. tRNA isopentenyl 
transferase uses isopentenyl pyrophosphate as the donor. Statins, the inhibitors 
of mevalonate pathway have been shown to interfere with tRNA(sec) maturation 
and the biosynthesis of GPX4, therefore enhancing cells’ sensitivity to  
ferroptosis88, 89. CoQ10, another product of mevalonate pathway, serves as an 
antioxidant in membrane to inhibit lethal lipid peroxidation77.  
 
P53 pathway: dual effects 
The tumor suppressor protein p53 have been discovered to play a key role in 
cellular response to different stresses, including DNA damage, hypoxia, nutrition 
starvation, and oncogene activation90. p53 serves as a lifeguard for cells and 
leads to either survival or death depending on the level of stress: the activation of 
p53 in response to low levels of stress results in cell cycle arrest, DNA repair and 
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survival; while the activation of p53 to high levels of stress leads to apoptosis and 
cell death91.  
 
In addition to its canonical role as a tumor suppressor, p53 has been identified as 
a novel regulator of ferroptosis recently92-95. Similar to its context-dependent role 
in response to stresses, p53 also plays a dual role in the control of ferroptosis. 
On one hand, p53 is able to suppress ferroptosis through the inhibition of 
dipeptidyl-peptidase-4 (DPP4) activity or promotion of p21 expression96: P53 has 
been shown to suppress ferroptosis by transforming DPP4 to the nucleus in 
colorectal cancer93;the stabilization of p53 by nutlin-3 shows a delayed initiation 
of ferroptosis in the presence of p2194. However, on the other hand, p53 can 
enhance ferroptosis by inhibiting SLC7A11 expression or promoting SAT1 
expression. Both WT p53 and the P533KR (K117R, K161R and K162R) mutant, 
which fail to induce apoptosis, have been found to target and repress the 
expression of SLC7A11, thereby inhibiting cystine uptake and increasing the 
sensitivity to ferroptosis95. SAT1 induction was found to be correlated with the 
expression levels of ALOX15, a lipoxygenase for lipid peroxidation92. The 
depletion of SAT1 is able to inhibit p53 and p533KR-induced ferroptosis92.  
 
1.3.4 Ferroptosis in physiological, pathological and therapeutic contexts 
Ferroptosis has been implicated in numerous human pathologies and therapeutic 
strategies, but a normal physiological function for ferroptosis has not been 
identified, except perhaps as a tumor suppression mechanism. A recent review 
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summarized the evidence for ferroptosis in models of a variety of degenerative 
diseases of the kidney, heart, liver, and brain, including models of Parkinson, 
Huntington, and Alzheimer diseases, dementia, and traumatic and hemorrhagic 
injuries72. 
 
Pathologies involving ferroptosis have also been found in contexts in which iron 
is abundant, such as in red blood cells. Indeed, ferroptosis has been implicated 
in the complications of blood transfusions. A recent study found that transfusion 
of storage-damaged red blood cells induces a macrophage-dependent 
inflammatory response by Ly6Chi monocytes97. Moreover, macrophages 
underwent ferroptosis following phagocytosis of storage-damaged red blood cells. 
This suggests that inhibitors of ferroptosis might improve outcomes of blood 
transfusion. Ferroptosis has also been linked to the iron-overload disease liver 
hemochromatosis72. 
 
As noted above, there are few reports of natural functions of ferroptosis. 
However, the p53 tumor suppressor has been suggested to use ferroptosis as a 
tumor suppression mechanism95, 98, suggesting that ferroptosis may have a 
natural function in suppressing the development of some tumors in mammals. 
Ferroptosis also may be useful for eliminating cancer cells that have become 
dependent on suppression of ferroptosis for their survival. Two recent studies 
found that some of the most drug-resistant and hard-to-kill cancer cells—namely, 
those that have undergone epithelial-to-mesenchymal transition89 and those that 
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persist after conventional chemotherapy or targeted therapy99—are highly 
sensitive to GPX4 inhibitors and ferroptosis in general. This suggests that 
ferroptosis-inducing agents might be developed as a new class of cancer 
therapies. 
 
Finally, ferroptosis may be involved in the toxic effects of environmental 
contaminants. A recent report found that mice fed arsenite in their drinking water 
exhibited increased neuronal ferroptosis100. Thus, ferroptosis markers may aid in 
detecting individuals exposed to arsenite in their drinking water, and ferroptosis 
inhibitors might be useful for such communities. 
 
1.4 Hallmarks of ferroptosis  
Three hallmarks, oxidation of PUFA-PLs, redox-active iron, and loss of lipid 
peroxide repair capacity, have been proposed as criteria to measure the extent to 
which ferroptosis occurs101 (Figure 1.6). 
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Figure 1.6 A schematic overview of three ferroptosis hallmarks. 
 
1.4.1 Lipid peroxidation 
Lipid peroxides are the direct trigger of ferroptosis. They are generated via two 
major mechanisms: the nonenzymatic free-radical chain reaction involving 
Fenton chemistry and enzymatic processes, most notably LOXs. Both 
mechanisms involve iron. Fenton chemistry refers to a series of reactions 
between peroxides and divalent ferrous salts to produce oxygen-centered 























However, there is a pool of loosely chelated iron in cells: while most cellular iron 
is bound to heme, there is soluble and chelatable ferrous iron in the cytoplasm 
which forms the labile iron pool103. This labile iron pool is the likely source of 
Fenton chemistry that generates hydroxyl and peroxyl radicals that are able to 
abstract hydrogen atoms from bis-allylic carbons of PUFAs and then cause 
peroxidation of PUFA-PLs. These reactions can be terminated by antioxidants 
and radicals104. Recent studies found that numerous inhibitors of ferroptosis—
including Fer-1, liproxstatin-1, and numerous LOX inhibitors—act as radical 
trapping antioxidants to prevent the autooxidation and nonenzymatic destruction 
of membrane PUFA-PLs likely driven by Fenton chemistry during ferroptosis105. 
Moreover, addition of excess iron to cells sensitizes them to ferroptosis73. 
 
There are three well-defined classes of lipid oxidation enzymes: 
cyclooxygenases (COXs), cytochrome p450 (CYPs), and LOXs, among which 
LOX enzymes have been found to be the most important for ferroptosis. LOXs 
are a family of nonheme, iron-containing enzymes that catalyze dioxygenation of 
PUFAs106. In the case of arachidonic acid (AA), there are 6 arachidonate 
lipoxygenase (ALOX) genes in 
humans: ALOX5, ALOX12, ALOX12B, ALOX15, ALOX15B, and ALOXE376. 
 
The mechanisms by which LOXs drive ferroptotic cell death, and the isoforms 
that drive this process, remain elusive. Several hypotheses have been proposed. 
One research group found that in mouse embryonic fibroblasts (MEF), 12/15-
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lipoxygenase-deficient cells were resistant to the lethality normally caused by 
GSH depletion using the GSH biosynthesis inhibitor buthionine sulfoximine 
(BSO)107. Another group found that silencing either ALOX15B or ALOXE3 
prevented erastin-induced cell death, which supported the hypothesis that LOXs 
are required for ferroptosis initiated by class 1 inducers76. The hypothesis that 
ALOX5 is involved in initiating ferroptosis was supported by the observation that 
deuteration at the 7 position of AA was protective against ferroptosis initiated by 
RSL379. It has been found that tumor cell ferroptosis is promoted by 15-
lipoxygenase-catalyzed lipid peroxidation in cellular membranes108.  
 
Acyl-CoA synthetase long-chain family 4 (ACSL4) and lysophosphatidylcholine 
acyltransferase 3 (LPCAT3) are also required in the formation of lipid peroxides. 
They act before LOXs. ACSL4 catalyzes the formation of AA-CoA. LPCAT3 
esterifies AA-CoA into AA-PE, the substrate for LOXs. ACSL has five isoforms 
ACSLs, ACSL1, ACSL3, ACSL4, ACSL5, and ACSL6 of which ACSL4 is closely 
related to ferroptosis. Gpx4-Acsl4 double knockout cells showed marked 
resistance to ferroptosis109. 
 
Moreover, it has been found that lipid peroxidation in endoplasmic-reticulum-
associated compartments occurs on phosphatidylethanolamines (PEs) only and 
is specific to fatty acyls-arachidonoyl (AA) and adrenoyl (AdA)110. 
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1.4.2 Redox-active iron 
Iron has two forms in the cells: Ferrous iron Fe(II) with the ability to transfer 
electrons and ferric iron Fe(III) for storage and transportation. Ferrous iron 
usually binds to protein and serves as a cofactor for various oxidation-reduction 
reactions. However, when there is an excess of ferrous iron, the ease in electron 
transfer makes ferrous iron toxic to cells by oxidizing proteins, lipid, and nucleic 
acids111.  
 
Iron is transported into cells via two mechanisms: heme iron transporter and 
transferrin-transferrin receptor. Transferrin receptor (TfR) can bind to transferrin 
(Tf) which can bind two Fe(III) to form diferric Tf. Then the Tf-Fe2-TfR complex is 
internalized via clathrin-mediated endocytosis. Fe(III) is then released into 
cytoplasm by DMT1 and Tf-TfR is recycled back to cell surface112, 113. It was 
reported that cells with knockdown of TfR1 became more resistant to erastin-
induced ferroptosis114 and TfR RNAi significantly inhibited serum-dependent 
necrosis turned out to be ferroptosis83. Unused iron is stored in ferritin. Nuclear 
receptor coactivator 4 (NCOA4) can bind to ferritin, release iron and deliver it to 
lysosomes for degradation115. It was found that NCOA4-mediated ferritinophagy 
increased the availability of intracellular iron and promoted ferroptosis116. 
Ferroportin (FPN) is the only iron exporter identified so far. It exports iron in Fe(II) 
which can then be oxidized by extracellular ferroxidase117.  
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Both of the two lipid peroxidation mechanisms – non-enzymatic Fenton reaction 
and enzymatic LOXs oxidation – require iron. That is why ferroptosis is defined 
as iron-dependent cell death and can be prevented by iron chelators. However, 
how iron regulates ferroptosis is still unclear. Further research is required to 
better illustrate their relationships. 
 
1.4.3 Defective lipid peroxide repair 
Glutathione peroxidase 4 (GPX4), responsible for the reduction of lipid peroxides 
to lipid alcohols in membrane environments, is the central regulator of ferroptosis. 
GPX4 is a selenoprotein that contains selenocysteine at its active site. Three 
types of GPX4 are identified: mGPX4 that is transported into the mitochondria118, 
nGPX4 for nucleoli 119and cGPX4 in cytosol and nuclei120. They are different in 
N-terminal signal sequence and transcribed by different start codons and exons.  
 
GPX4 catalyzes the reduction of hydroperoxides through the oxidation of the 
active site selenol (Se-H) to selenenic acid (Se-OH). Glutathione (GSH) is used 
as a cofactor and substrate to reduce Se-OH back to the active Se-H121. 
All of the ferroptosis inducers either indirectly or directly interact with GPX4. 
Overexpression of GPX4 results in resistance to RSL3-induced ferroptosis while 
knockdown of GPX4 induces ferroptotic cell death, which could be rescued by an 
iron chelator (DFOM), a MEK inhibitor (U0126) and an antioxidant (vitamin E)75. 
Moreover, all ferroptosis inducers inactivate GPX4 directly or indirectly. RSL3 
directly binds to GPX4 to inhibit its enzymatic function. Erastin, IKE and other 
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class 1 ferroptosis inducers deplete glutathione and inhibit GPX4 activity. FIN56 
is able to deplete GPX4 and FINO2 indirectly inactivates GPX4.  
 
In addition to GPX4-mediated lipid hydroperoxides repair, there are also 
alternative antioxidant pathways involved in ferroptosis, including those of CoQ10 
and vitamin E.  
 
1.4.4 Methods to detect cells undergoing ferroptosis 
The fluorescent probes C11-BODIPY and LiperFluo are most commonly used as 
indicators of lipid peroxidation. BODIPY-C11 indicates the production of reactive 
oxygen species (ROS) in a lipophilic environment through a change in 
fluorescence emission wavelength of the probe, detected by a fluorescent signal 
ratio. It is sensitive to the free radical species formed from hydroperoxides, but 
not the hydroperoxides themselves122. In contrast, Liperfluo directly reacts with 
lipid hydroperoxides to form highly fluorescent Liperfluo-OX, which can be 
detected at long wavelengths123. The increase of redox-active iron is measured 
by an iron assay, which quantitatively determines the ratio of ferrous (Fe2+) to 
ferric (Fe3+) iron. Loss of lipid peroxide repair is commonly determined by the 
enzymatic activity of GPX4. NADPH is added as an indicator of the ability of 
GPX4 to oxidize its substrate and cofactor GSH. However, these experiments 
are not straightforward, are limited to biochemical assays, and cannot be used in 
fixed tissue sections. 
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A ferroptosis-specific antibody would allow us to examine the consequences of 
ferroptosis in a variety of contexts, including both tissue sections and cells in 
culture. A specific indicator of ferroptosis could be used as a tool for in situ 
labeling, which has become increasingly important, as the biological relevance of 
ferroptosis becomes more apparent. Several antigens have been proposed for 
this purpose. PTGS2, encoding cyclooxygenase-2 (COX-2) was the most 
upregulated gene in BJeLR cells upon treatment with either erastin or RSL3 in a 
survey of 83 genes75. CHAC1 (cation transport regulator homolog 1), an ER 
stress response gene, was found to be upregulated during the inhibition of 
system xc-124.  RT-qPCR is commonly used to measure the mRNA level of 
PTGS2 and CHAC1 in cells. However, the application of antibodies against these 
proteins is more challenging.  
 
Acyl-CoA synthetase long-chain family member 4 (ACSL4) was found to be 
required for ferroptotic cell death125. The expression of ACSL4 was 
downregulated in ferroptosis-resistant cells compared to ferroptosis-sensitive 
cells. However, it is not clear whether the expression level of ACSL4 changes for 
ferroptosis-sensitive cells undergoing ferroptosis.  
 
MDA (malondialdehyde) and 4-HNE (4-hydroxynonenal) are aldehydic secondary 
products of lipid peroxidation. Antibodies against these species are candidate 
ferroptosis markers. The anti-MDA 1F83 antibody has been used as a ferroptosis 
marker in mouse lymphoma xenograft model tumor tissues126. However, this 
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species is also a marker of oxidative stress, and may not be specific for 
ferroptosis compared to other oxidative stress contexts.  
 
1.5 Overview of dissertation 
The dissertation is about how to use molecular screens to design small-molecule 
inhibitors for oncogenic K-RasG12D protein and to identify staining reagents for 
ferroptosis. In the first chapter, I discuss the background of Ras proteins and 
ferroptosis. In the second chapter, I describe how we used computational 
methods to discover a potential allosteric small-molecule binding site, termed the 
P110 site, on K-RasG12D. In the third chapter, I describe the discovery of KAL-
21404358, a small-molecule inhibitor of K-RasG12D. We started with 
computational high-throughput screen and then validated the binding by 
biophysical and biochemical assays. We also evaluated the ability of KAL-
21404358 to interrupt K-RasG12D-B-Raf interaction and downstream signaling 
pathways. In the final part of this chapter, I describe the modification of the KAL-
21404358 scaffold. In the fourth chapter, I describe the generation of a pool of 
unknown target monoclonal antibodies and then discuss the phenotypic screen 
and the identification of 3F3-FMA as a ferroptosis marker. We identified the 
antigen of 3F3-FMA as transferrin receptor protein 1 (TfR1). In the fifth chapter, I 
discuss the applications of anti-TfR1 antibodies and other potential ferroptosis 
staining reagents in immunofluorescence, flow cytometry, western blot, and 
tissue sections. In the last chapter, I summarize the two projects and discuss the 
next step and perspectives. 
 40 
Chapter 2 K-RasG12D has a potential allosteric small molecule binding site2 
2.1 Introduction 
Despite the high prevalence of K-Ras mutations in human cancers, K-Ras is still 
an “undruggable” target. K-Ras is considered a challenging drug target for two 
main reasons. First, there does not seem to be a deep, hydrophobic pocket on 
the surface of K-Ras suitable for potent and selective small molecule binding; the 
only notable binding pocket on K-Ras is the nucleotide binding pocket, which 
binds GTP/GDP with picomolar affinity, making it an impractical target site for 
small molecule drugs127. Second, K-Ras, like roughly 85% of other human 
proteins, exerts its biological effects via protein–protein interactions, which are 
often difficult to disrupt with small molecules, due to their large surface areas and 
the diffuse nature of the interactions between them128. 
 
Here we defined a potential pocket, the P110 site, near the C-terminus of K-
RasG12D using Schrödinger Suites-based computational methods. The P110 site 
involves residues Arg97, Asp105, Ser106, Glu107, Asp108, Val109, Pro110, 
Met111, Tyr137, Gly138, Ile139, Glu162, Lys165, and His166. We first performed 
SiteMap on 4DSN crystal structure to pick up the best small-molecule binding 
                                            
2 This chapter is adapted from the manuscript: Huizhong Feng, Yan Zhang, Pieter H. 
Bos, Jennifer M. Chambers, Marcel M. Dupont, and Brent R. Stockwell. K-RasG12D Has a 





site where P110 site stood out. Then, we validated the P110 site by comparing 
4DSN with other Ras isoforms. P110 site appeared in these structures as well, 
but not as apparent. We then performed MD simulations to catch the P110 site in 
a dynamic environment. MxMD simulations were conducted to reveal if the P110 
site could be accessible to small molecules. 
 
2.2 Results 
2.2.1 SiteMap of K-RasG12D and other isoforms  
Given the challenges of directly targeting the nucleotide binding site and effector 
interaction surface, we hypothesized there might be allosteric pockets regulating 
the on and off cycle of K-Ras. To identify such sites, we first performed 
computational analysis of the K-RasG12D crystal structure (PDB entry 4DSN) 
using the SiteMap (Schrödinger Suites) prediction tool129, 130.The P110 site had 
the highest score for a potential small molecule binding site 
(r_sitemap_SiteScore = 0.92) and identified a binding site including residues 
Arg97, Asp105, Ser106, Glu107, Asp108, Val109, Pro110, Met111, Tyr137, 




Figure 2.1 Model of K-RasG12D (PDB entry 4DSN) with the P110 site. 
 
The P110 site (colored red) residues are Arg97, Asp105, Ser106, Glu107, 
Asp108, Val109, Pro110, Met111, Tyr137, Gly138, Ile139, Glu162, Lys165, and 
His166. 
 
To explore the potential robustness of the P110 site across different protein 
conformations, we conducted similar analyses of other crystal structures of K-
Ras (PDB entries 4EPR, 4OBE and 5VQ2) and other Ras isoforms H-Ras (PDB 
entry 4L9W) and N-Ras (PDB entry 3CON). We found that the P110 site still 
appeared across these structures, but the SiteMap scores were not as high as in 
structure 4DSN (Table 2.1). This indicates that the P110 site is more apparent in 
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Arg97, Asp105, Ser106, Glu107, Asp108, Val109, Pro110, 





Arg97, Glu107, Asp108, Val109, Pro110, Met111, Tyr137, 





Arg97, Glu107, Asp108, Val109, Pro110, Met111, Tyr137, 





Arg97, Ile100, Lys101, Glu107, Asp108, Val109, Pro110, 





Arg97, Asp107, Asp108, Val109, Pro110, Met111, Tyr137, 





Arg97, Asp107, Asp108, Val109, Pro110, Met111, Tyr137, 
Gly138, Ile139, Glu162, His166 
Table 2.1 P110 site on other RAS isoforms 
 
The P110 site appeared in SiteMap (Schrödinger Suites) of other RAS isoforms, 
but the Site Scores were not as favorable as in 4DSN. Protein PDB ID, 
description of the proteins, Site Scores and residues involved were listed.  
 
Computational analysis of the P110 site on 4DSN (orange) and 4EPR (blue) 
showed different poses of residues Arg97, Asp105, Ser106, Glu107, Asp108, 
and Lys165 (Figure 2.2). These conformational changes make the P110 site on 
GTP-bound K-RasG12D open and larger than those on GDP-bound K-RasG12D. 
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Figure 2.2 Computational comparison of P110 site of 4DSN (orange) and 4EPR 
(blue) 
 
Residues Arg97, Asp105, Ser106, Glu107, Asp108 and Lys165 have different 
conformation. These changes make the P110 site on GTP-bound K-RasG12D more 
open and larger.  
 
Computational analysis of the P110 site on 4DSN (orange) and 5VQ2 (yellow) 
showed different poses of residues Arg97, Asp105, Ser106, Glu107, Asp108, 
Met111, Tyr137, Lys165 and His166 (Figure 2.3). These conformational changes 
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Figure 2.3 Computational comparison of P110 site of 4DSN (orange) and 5VQ2 
(yellow) 
 
Residues Arg97, Asp105, Ser106, Glu107, Asp108, Met111, Tyr137, Lys165 and 
His166 have different conformation. These changes make the P110 site on K-
RasG12D mutation more open and larger.  
 
Comparison of P110 sites of 4DSN (orange) with those of 4L9W (green) showed 
different poses of residues Asp105, Ser106, Glu107, Asp108, Pro110, and 
Met111, making the P110 site open and larger in K-Ras (Figure 2.4). These 
observations suggest that the P110 site is specific to K-Ras and is not as 
apparent in H-Ras or N-Ras, at least in the X-ray structures currently available. 
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Figure 2.4 Computational comparison of P110 sites of 4DSN (orange) with 4L9W 
(green) 
 
 Residues Asp105, Ser106, Glu107, Asp108, Pro110 and Met111 have different 
conformation, making P110 site open and larger in K-Ras. 
 
2.2.2 Molecular dynamics (MD) simulations 
Next, we performed a molecular dynamics (MD) simulation to mimic different 
conformations of K-RasG12D other than the ones found in the crystal structures. 
Twenty clusters were generated from a 200 ns MD simulation. The P110 site 
appeared consistently in these simulations, of which one cluster (#6) showed the 
best SiteMap score of 1.06 (Figure 2.5). This suggests that this pocket can 
become even more accessible during the motion of the K-RasG12D protein. 
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Figure 2.5 The P110 site appeared in MD simulation model of K-RasG12D 
 
MD simulation was performed with Desmond (Schrödinger Suites). 20 clusters 
were generated from a 200 ns MD simulation. Cluster 6 showed the best Site 
Score at 1.06. Residues included Arg97, Asp105, Ser106, Glu107, Asp108, 
Val109, Pro110, Met111, Tyr137, Gly138, Ile139, Glu162, Lys165 and His166. 
 
2.2.3 Mixed Solvent Molecular Dynamics (MxMD) simulations 
MxMD simulations were then run with structure 4DSN using acetonitrile, 
isopropanol, pyrimidine, acetone, imidazole, and N-methylacetamide as organic 
probes. These organic probes can affect the conformation of K-RasG12D and 
reveal which sites can be accessible to small molecules of various 
chemotypes131, 132. The P110 site was found to contain all of these solvents as a 




P110 site on K-RasG12D MD simulation cluster 6 model






P110 site contains all six organic solvents
D E
Comparison of P110 sites of 4DSN (orange) with 4L9W (green)Comparison of P110 sites of 4DSN (orange) with 4EPR (blue)
!"#$%&'(!)*(+)( )%,-"&./#'( 0&$%(0-#"%( 1%,&23%,(&'4#54%2(
6)07( 89!:;#3'2(<:1=,8>?)( @AB?( C"DBEF(C,.>@GF(0%">@HF(853>@EF(C,.>@IF(J=5>@BF(!"#>>@F(K%$>>>F(LM"(>NEF(85M>NIF(+OP>NBF(853>H?F(OM,>HGF(='2(Q&,>HH((
6P!1( 8)!:;#3'2(<:1=,8>?)( @AHI( C"DBEF(853>@EF(C,.>@IF(J=5>@BF(!"#>>@F(K%$>>>F(LM">NEF(85M>NIF(+OP>NBF(853>H?F(OM,>HGF(Q&,>HH(
6R*P( 8)!:;#3'2(<:1=,8>?9( @AGB( C"DBEF(853>@EF(C,.>@IF(J=5>@BF(!"#>>@F(K%$>>>F(LM">NEF(85M>NIF(+OP>NBF(!"#>6@F(853>H?F(OM,>HGF(Q&,>HH(
N9R7( 8)!:;#3'2(7:1=,( @AGH( C"DBEF(C,.>@EF(C,.>@IF(J=5>@BF(!"#>>@F(K%$>>>F(LM">NEF(+OP>NBF(853>H?F(Q&,>HH(
6OBS( 8K!!7!:;#3'2(Q:1=,8>?9( @AHH( C"DBEF(C,.>@EF(C,.>@IF(J=5>@BF(!"#>>@F(K%$>>>F(LM">NEF(85M>NIF(+OP>NBF(853>H?F(Q&,>HH(
 
 48 
             
Figure 2.6 MxMD simulations  
 
The P110 site contained all six organic solvents - acetonitrile, isopropanol, 
pyrimidine, acetone, imidazole, and N-methylacetimide (green, blue, yellow, 
orange, red and purple). 
 
 
2.3 Conclusion and discussion 
In summary, the P110 site was validated to exist on K-RasG12D by computational 
prediction. However, we did not know if the binding of a small molecule to this 
site would disrupt Ras signaling. To further elucidate this site, the next step was 
to discover small molecule inhibitors with high binding affinity and allosteric effect.  
 
2.4 Methods 
Software and Computational Methods 
Molecular dynamics (MD) simulations, mixed solvent molecular dynamics (MxMD) 
simulations, molecular docking, and modeling were performed using Maestro 
(Schrödinger Suite), Molecular Operating Environment (MOE), and PyMOL. 
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Chemical structures were drawn using ChemDraw Professional 16.0. Statistical 
analyses were performed using Prism 7.0 (GraphPad Software). Libraries of 
commercially available compounds were compiled from the inventories of Asinex, 
Enamine, Chembridge, ChemDiv, IBS, Life, May-bridge, and TimTec. A fragment 
subset of ∼3.5 million compounds was selected and screened.  
Protein Data Bank (PDB) structures were imported in Maestro (Schrödinger 
Suite). Structures were preprocessed, optimized, and minimized using default 
settings by Protein Preparation Wizard (Schrödinger Suite). SiteMap (Schrö- 
dinger Suite) was run using the default setting. MD simulations were performed 
with Desmond Molecular Dynamics (Schrö- dinger Suite). The total simulation 
time was 200 ns. Twenty representative clusters were then generated using the 
default setting of RMSD Based Clustering Of Frames From Desmond Trajectory 
(Schrödinger Suite). MxMD simulations were run by scripts. Ten protein 
cosolvent boxes for each of six probes (acetonitrile, isopropanol, pyrimidine, 
acetone, imidazole, and N-methylacetimide) were first generated by a shell script. 
MxMD simulations were then performed by a “run_cosolvent_simulations.sh” 
script. The map was finally generated by “01_generate_occupancy.sh” and 
“02_generate_maps.sh” scripts.  
The P110 site was selected using Receptor Grid Generation (Schrödinger Suite) 
by specifying residue Pro110 as the center of the enclosing box. No constraints 
were defined. Different poses of compounds were generated by defining 
ionization states from pH 4.0 to 7.0 and stereoisomers using LigPrep 
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(Schrödinger Suite). Ligand Docking (Schrödinger Suite) was then used to 
calculate the Glide Docking Scores. A lower score meant a higher binding affinity. 
WaterMap (Schrödinger Suite) was run by defining KAL-21404358 ligand 





































































































































Chapter 3 KAL-21404358 is a small-molecule inhibitor of K-RasG12D 3  
3.1 Introduction 
Following the finding of the P110 site, in this chapter I will describe a strategy for 
targeting oncogenic K-Ras by combining computational methods and 
biochemical assays. Using virtual screening, we discovered a candidate P110 
site binding compound, termed KAL-21404358. Then we used biochemical 
assays to validate the binding of KAL-21404358. A combination of microscale 
thermophoresis (MST), a thermal shift assay (TSA), line broadening nuclear 
magnetic resonance (NMR), and heteronuclear single-quantum coherence 
(HSQC) NMR demonstrated binding of KAL-21404358 to K-RasG12D with a KD of 
100 μM and allosteric effects on switch I and switch II. KAL-21404358 was 
further found to disrupt the K-RasG12D–B-Raf interaction using a NanoBiT split 
luciferase assay and to impair the Raf-MEK-ERK and PI3K-AKT signaling 
pathways. We designed analogues to define the structure–activity relationship 
around the KAL scaffold. These findings suggest that the P110 site may be an 
allosteric regulatory site for targeting oncogenic K-RasG12D. Moreover, this 
structure-based approach provides a strategy for discovering small molecule 
inhibitors for otherwise challenging drug targets. 
                                            
3 This chapter is adapted from the manuscript: Huizhong Feng, Yan Zhang, Pieter H. 
Bos, Jennifer M. Chambers, Marcel M. Dupont, and Brent R. Stockwell. K-RasG12D Has a 




3.2.1 Computational high-throughput screen 
We tested 3.5 million compounds using the Glide docking algorithm (Schrödinger 
Suites), which generates a score in which the more negative the score, the 
higher the predicted affinity133. 77 fragments with scores of less than −6.5 were 
obtained for further validation. Four rounds of biochemical screening using MST, 
TSA, NMR line broadening, and HSQC NMR spectroscopy were used to select 
promising compounds from among these 77 candidates. KAL-21404358 was the 
most favorable compound, as it showed positive binding results in all four tests. 
 
KAL-21404358 was predicted to interact well with the P110 site, with a Glide 
docking score of −7.37 (Figure 3.1, left). A closer view of KAL-21404358 in the 
P110 site showed four potential hydrogen bonds (between the −NH in the 
hydroxyquinoline and the carboxyl group of Asp108, between the −OH in the 
hydroxyethyl group and the carboxyl group of Glu107, and two between the −OH 
in the hydroxyethyl group and the amine group of Arg97) as well as strong polar 
interactions (between the bridge of KAL-21404358 and the amide group of 
Glu107 and between the piperazinyl group and the amide group of Gly138) 
(Figure 3.1, right). 
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Figure 3.1 KAL-21404358 binding pose 
 
Left, KAL-21404358 docking pose in the P110 site and its structure, docking 
score, chemical formula, mass, and molecular weight. Right, detailed view of 
KAL-21404358 binding in the P110 site. Four potential hydrogen bonds are 
labeled with green lines.  
 
3.2.2 WaterMap 
WaterMap (Schrödinger Suite) was then used to estimate changes in the 
thermodynamic properties resulting from water molecule displacement by 
fragments binding in the P110 site134, 135. Four high-energy water molecules were 
predicted to be located in the P110 pocket superimposed upon KAL-21404358, 
which suggested that displacement of these water molecules would improve the 
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Figure 3.2 KAL-21404358 superimposed with four high-energy water molecules 
colored red with ΔG > 2 and purple with ΔG > 1. 
 
3.2.3 Biochemical validation of KAL-21404358 binding with K-RasG12D 
MST and TSA were used as first-line screening methods. The KD of KAL-
21404358 for GppNHp-bound K-RasG12D was 88 μM, and the KD with GDP-
bound K-RasG12D assessed by MST was 146 μM (Figure 3.3). This suggests that 
KAL-21404358 has a slightly higher binding affinity for the GppNHp-bound form 
of K-RasG12D.  
 
Figure 3.3 MST validation of binding of KAL-21404358 to K-RasG12D 
 
Left, MST assay of KAL-21404358 with GppNHp-bound K-RasG12D (KD= 88 ± 1 
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MST: GppNHp bound K-RasG12D with 21404358
Kd= 88 µM ± 1 µM










MST: GDP-bound K-RasG12D with KAL-21404358
Kd= 146 µM ± 2 µM
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and are representative of five independent experiments. Right, MST assay of 
KAL-21404358 with GDP-bound K-RasG12D (KD = 146 ± 2 μM) indicating 
selectivity toward GppNHp-bound vs GDP-bound K-RasG12D. Data are means ± 
SD of triplicate measurements and are representative of five independent 
experiments. 
 
TSA experiments confirmed a 2.1 °C melting temperature shift, indicating binding 
of KAL-21404358 stabilizes GDP-bound K-RasG12D to thermal denaturation, 
possibly further inhibiting activation of GDP-K-RasG12D (Figure 3.4). The binding 
of KAL-21404358 to GppNHp-bound K-RasG12D did not cause a temperature shift 
(Figure 3.5). 
 
Figure 3.4 TSA validation of binding of KAL-21404358 to K-RasG12D 
 
KAL-21404358 increases the melting temperature of K-RasG12D in a thermal shift 
assay. Data are means ± SD of triplicate measurements and are representative 
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Figure 3.5 TSA of GppNHp-bound K-RasG12D (green), 500 µM KAL-21404358 
and GppNHp-bound K-RasG12D (cyan) and 1000 µM KAL-21404358 and 
GppNHp-bound K-RasG12D (magenta).  
 
There was no melting temperature shift with the binding of KAL-21404358, 
suggesting no difference in melting temperature of state 1 and state 2 for 
GppNHp-bound KRASG12D. 
 
To test whether KAL-21404358 bound specifically to the P110 site, we 
constructed four mutants predicted to be deficient for binding to KAL-21404358: 
R97G, E107A, D108A, and P110D. No binding between KAL-21404358 and 
these four mutants was detected using MST, supporting the hypothesis that this 
compound binds in the P110 site (Table 3.1; the original MST curves are shown 
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Protein KAL-21404358 KD (µM) by MST 
GDP-K-RasG12D 146 ± 2 
GDP-K-RasG12D R97G No binding 
GDP-K-RasG12D E107A No binding 
GDP-K-RasG12D D108A No binding 
GDP-K-RasG12D P110D No binding 
Table 3.1 KAL-21404358 lacks binding to P110 site mutants 
 




Figure 3.6 MST assay of KAL-21404358 with four binding-deficient mutants K- 
RasG12D R97G, K-RasG12D E107A, K-RasG12D D108A, and K-RasG12D P110D. 
 
KAL-21404358 did not bind detectably to these four mutants. Data shown are 
representative of triplicates in one independent experiment. 
 
We also examined the specificity of KAL-21404358 for K-RasG12D over K-RasWT, 
H-RasWT, Rap1a, R-Ras, and R-Ras2. Each protein was tested for its ability to 
bind to KAL-21404358 using MST. Much weaker binding of KAL-21404358 was 
detected toward these other proteins, suggesting that KAL-21404358 has 
selectivity for K-RasG12D (Table 3.2; the original MST curves are shown in Figure 
3.7). 
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Protein KAL-21404358 KD (µM) by MST 
GppNHp-K-RasG12D 88 ± 1 
GppNHp-K-RasWT 525 ± 2 
GppNHp-H-RasWT 1888 ± 1 
GppNHp-Rap1a 350 ± 2 
GppNHp-R-Ras 480 ± 2 
GppNHp-R-Ras2 897 ± 1 
Table 3.2 KAL-21404358 has differential selectivity for K-RasG12D compared to 
other RAS family member proteins 
 




Figure 3.7 MST assay of KAL-21404358 with GDP-bound K-RasG12D and other 
Ras family proteins 
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The binding affinities of KAL-21404358 with K-RasWT, H-RasWT, Rap1a, R-Ras 
and R-Ras2 are lower than with K-RasG12D, suggesting the specificity of KAL-
21404358 to K-RasG12D. Data shown as mean ± SD of triplicates and are 
representative of one independent experiment. 
 
To further elucidate how KAL-21404358 binds to K-RasG12D, we used NMR line 
broadening. The disappearance of hydrogens 1, 5, 6, 14, 15, 17, and 18 in the 1H 
NMR spectrum of the compound indicated binding to K-RasG12D, which is likely 
due to these being the interacting atoms on KAL-21404358 (Figure 3.8). Analysis 
of the structure of KAL-21404358 suggested that it bound to K-RasG12D with the 
quinolinol and piperazinyl group, but not the neopentyl group, which was 
consistent with the computational prediction. 
 
Figure 3.8 NMR line broadening validation of binding of KAL-21404358 to K-
RasG12D 
 
NMR line broadening experiment of KAL-21404358 with an increased 
concentration of K-RasG12D (1:0, 1:0.3, 1:1, and 0:1 ratios). Peaks of hydrogens 
of quinolinol and the piperazinyl group (colored red) were broadened, indicating 




HSQC NMR was then used to identify the residues on K-RasG12D that change 
upon KAL-21404358 binding to test for possible allosteric effects. Conformational 
changes in the switch I and switch II regions (Asp33, Ser39, Leu56, Gly60, 
Met67, Thr74, and Gly75) were observed in GDP-bound K-RasG12D (Figure 3.9) 
upon KAL-21404358 binding, suggesting an allosteric effect on the K-
RasG12D conformation. However, KAL-21404358 interacted with only side chains 
of residues, as no backbone shifts near the P110 residues were observed in the 
HSQC NMR experiments. 
 
Figure 3.9 HSQC NMR experiment showing conformational changes in switch I 
and switch II of K-RasG12D, which could be explained by P110 site’s allosteric 
effect.  
 
Blue represents GDP-bound K-RasG12D and red represents GDP-bound K-
RasG12D with KAL-21404358 at a 1:7 concentration ratio. Residues changed upon 
binding with KAL-21404358 are labeled. 
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3.2.4 Inhibition of the K-RasG12D-B-Raf interaction 
On the basis of KAL-21404358’s binding mode, we tested whether this 
compound could disrupt the interaction between K-RasG12D and B-Raf using a 
NanoBiT split luciferase assay136. K-RasG12D was fused to SmBiT, and B-Raf was 
fused to LgBiT. The Ras–Raf interaction inhibitor 3144 was used as a positive 
control for disruption of the interaction55. KAL-21404358 and its analogue, KAL-
YZ0965, exhibited a luminescence lower than that of DMSO-treated control 
samples, suggesting that these compounds disrupted the K-RasG12D–B-Raf 
interaction (Figure 3.10, left). KAL-21404358 is more effective at lower 
concentrations, whereas KAL-YZ0965’s effectiveness was low. The compounds 
were simultaneously tested in cells with SmBiT/LgBiT to rule out nonspecific 
inhibition (Figure 3.10, right).  
 
Figure 3.10 KAL-21404358 inhibits the K-RasG12D–B-Raf interaction in NanoBit 
 
Left, a NanoBiT split luciferase assay showed that KAL-21404358 and its 
analogue KAL-YZ0965 disrupted the K-RasG12D–B-Raf interaction. 3144 was 
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LgBiT, and constructs were transfected in HEK293T cells. Luminescent signals 
were detected when K-RasG12D bound to B-Raf. Ordinary one-way analyses of 
variance were conducted in Prism 7. Four asterisks indicate p < 0.0001. Three 
asterisks indicate p < 0.001. ns indicates p > 0.05. Data are means ± SD of 
quadruplicate measurements and are representative of three independent 
experiments. Right, KAL-21404358, KAL-YZ0965, and 3144 were screened 
against SmBiT-LgBiT to rule out nonspecific inhibition and toxicity. Data are 
means ± SD of triplicate measurements and are representative of three 
independent experiments.  
 
A K-RasG12D–Raf-1–RBD pull-down assay was also conducted to validate 
disruption of this interaction. Less K-RasG12D was bound to Raf-1–RBD beads in 
the presence of KAL-21404358, which supported the hypothesis that this 
compound disrupts this interaction in cells (Figure 3.11). 
 
Figure 3.11 KAL-21404358 inhibits the K-RasG12D–B-Raf interaction in pulldown 
 
LS513 cells (with K-RasG12D) were treated with KAL-21404358 as indicated, and 
the amounts of Raf-1–RBD-bound K-RasG12D proteins were determined. Data are 
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3.2.5 KAL-21404358 inhibits K-RasG12D signaling pathways 
Next, the effect of KAL-21404358 on downstream Raf-Mek-Erk and PI3K-Akt-
mTor pathways was investigated. Less cellular phosphorylated Akt and 
phosphorylated Erk were detected after treatment of cells with KAL-21404358 
(Figure 3.12). However, the inhibitory effect of KAL-21404358 in the pull-down 
and Western assays was not strong, consistent with a low binding affinity. 
Further optimization of this compound or other compounds that bind in this site is 
needed to enable efficient allosteric inhibition of K-RasG12D in cells. 
 
 
Figure 3.12 KAL-21404358 inhibits K-RasG12D-dependent signaling. 
 
Effects of KAL-21404358 on the abundance of phosphorylated Akt and total Akt 
(left) and phosphorylated Erk and total Erk (right) were determined at the 
indicated concentrations in LS513 cells (with K-RasG12D mutations). LS513 cells 
from ATCC (catalog no. CRL-2134) were seeded 16 h prior to use in 10% FBS in 
RPMI-1640. The medium was then aspirated and replaced with serum-free 
medium containing KAL-21404358, and cells were incubated for 24 h. Relative 
intensities of phosphorylated forms vs total forms were quantified and are labeled. 
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3.2.6 Modification of the KAL-21404358 scaffold  
To optimize the properties of KAL-21404358, we designed and synthesized a 
series of close structural analogues. We divided KAL-21404358 into four 
functional groups: the hydroxyquinoline (blue), the bridge (green), the amine 




Table 3.3 A list of KAL-21404358 analogues 
 
Four functional groups are labeled: hydroxyquinoline in blue, bridge in green, 
amine group in black, and neopentyl group in red. KAL-21404358 analogue 
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names, structures, and KD values measured by MST and HSQC NMR are shown. 
More active compounds are shown in bold. 
 
First, we hypothesized that the neopentyl group might be replaced to improve 
properties of the compounds, because (1) it did not interact with the P110 pocket 
in the computational models and (2) this group is hydrophobic, decreasing the 
aqueous solubility of the compound. We thus identified and tested seven KAL-
21404358 analogues (red background) that had replacements of the neopentyl 
group only. The binding affinities of these compounds, as assessed by MST, 
were not improved, consistent with a lack of interaction at this site. These 
replacements did not generate new interactions between compounds and the 
receptor, likely because this group is facing the solvent.  
 
We next focused on the hydroxyquinoline moiety, which fits well into the P110 
pocket. Our hypothesis was that adding functional groups or changing the 
hydroxyquinoline moiety might form new hydrogen bonds between KAL-
21404358 analogues and K-RasG12D, thereby improving binding. Six KAL-
21404358 analogues (blue background) were identified and tested, among which 
analogue KAL-11067146 (bold) showed more potent binding in the MST assay 
(Table 3.3). However, this analogue did not affect the K-RasG12D conformation in 
an HSQC NMR experiment, suggesting a loss of allosteric inhibitory activity. 
Computational docking did not show the presence of a hydrogen bond formed by 
the addition of the fluorine (Figure 3.13), consistent with the NMR result. 
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Figure 3.13 KAL-11067146 docking pose in the P110 site 
 
KAL-11067146 has a docking pose similar to that of KAL-21404358. Addition of a 
fluorine molecule did not improve the binding of KAL-11067146 to the receptor. 
Potential hydrogen bonds are labeled with green lines.  
 
Next, we added a carbonyl group to the bridge region to increase the number of 
hydrogen bond interactions with K-RasG12D and also to increase the hydrophilicity 
of KAL-21404358. Considering the difficulty of synthesizing the hydroxyethyl 
piperazinyl moiety, we decided to replace it with other cyclic amines. Three 
analogues were synthesized, and one was commercially available, among which 
KAL-PHB6002, KAL-PHB6003, and KAL-2241124388 exhibited more potent 
binding in the MST assay. Computational docking showed a reverse pose for 
KAL-PHB6003 in the P110 site as an example of this series of analogues 
(Figure 3.14). Two potential hydrogen bonds are likely to be formed between the 
oxygen molecule of the hydroxyquinoline and the amine group of Lys165 as well 
as between the amine group of the bridge and the carboxyl group of Glu162.  
KAL-11067146 docking pose in P110 site
A










Figure 3.14 KAL-PHB6003 has a reverse docking pose compared to that of KAL-
21404358. 
 
Potential hydrogen bonds are labeled with green lines. 
 
However, HSQC NMR experiments again showed the lack of an allosteric 
inhibitory effect of KAL-PHB6002 and KAL-PHB6003. The chemical shifts (Asp33, 
Ser39, Leu56, and Gly75) of binding of KAL-2241124388 to K-RasG12D were the 
same with KAL-21404358 (Figure 3.15). No backbone chemical shifts of the 
P110 site were observed. The NanoBiT split luciferase assay showed a trend 
toward a weaker luminescence signal in the presence of KAL-2241124388 
(Figure 3.16). 
KAL-11067146 docking pose in P110 site
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Figure 3.15 NMR HSQC experiments showed chemical shifts of KAL-
2241124388 
 
It had similar residue shifts with KAL-21404358, but not as apparent. No 
backbone shifts of the P110 site were observed. Blue represents GDP-bound K-
RasG12D and red represents GDP-bound K-RasG12D with KAL-2241124388 at 






















































































































































































































































































































Figure 3.16 NanoBiT assay showed that KAL-2241124388, KAL-55883121, KAL-
YZ0968, and KAL-YZ0970 interrupted K-RasG12D-B-Raf interaction. 
 
K-RasG12D was fused to SmBiT and B-Raf was fused to LgBiT, and constructs 
were transfected in HEK293T cells. Luminescent signals were detected when K-
RasG12D bound to B-Raf. Ordinary one-way ANOVA test were conducted in Prism 
7. ** indicates p ≤ 0.01 * indicates p ≤ 0.05 and ns indicates p > 0.05. 
Compounds were simultaneously screened against SmBiT-LgBiT to rule out non-
specific inhibition and toxicity. Data shown as mean ± SD of triplicates and are 
representative of three independent experiments. 
 
We further synthesized 15 analogues with carbonyl bridges and cyclic amines. 
Three of these compounds (KAL-YZ0965, KAL-YZ0968, and KAL-YZ0970, gray 
background and bold) exhibited higher binding affinity as determined by MST and 
chemical shifts in HSQC NMR experiments (Table 3.3). The chemical shifts of 
these compounds in HSQC NMR experiments were similar to those of KAL-
21404358 but not as apparent (Figure 3.17). No backbone chemical shifts of the 
P110 site were observed.  
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Figure 3.17 NMR HSQC experiments showed chemical shifts of KAL-YZ0965, 
KAL-YZ0968 and KAL-YZ0970 
 
They had similar residue shifts with KAL-21404358, but not as apparent. No 
backbone shifts of the P110 site were observed. For KAL-YZ0965, blue 
represents GDP-bound K-RasG12D only, red represents GDP-bound K-RasG12D 
with KAL-YZ0965 at 1:10 concentration ratios and green represents GDP-bound 
K-RasG12D with KAL-YZ0965 at 1:20 concentration ratios. For KAL-YZ0968, blue 
represents GDP-bound K-RasG12D only, red represents GDP-bound K-RasG12D 
with KAL-YZ0968 at 1:12 concentration ratios and green represents GDP-bound 
K-RasG12D with KAL-YZ0968 at 1:24 concentration ratios.For KAL-YZ0970, blue 
represents GDP-bound K-RasG12D and red represents GDP-bound K-RasG12D 
with KAL-YZ0970 at 1:20 concentration ratios. Residues changed upon binding 
with KAL-21404358 analogs are labeled. 
 
Computational docking showed that KAL-YZ0965 fit well into the P110 site, as an 
example of this series of analogues. The addition of an amide group as the 
bridge could form two potential hydrogen bonds with K-RasG12D, stabilizing the 
binding of KAL-YZ0965 (Figure 3.18).  
A
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Figure 3.18 KAL-YZ0965 has a docking pose similar to that of KAL-21404358 
 
Addition of a carbonyl group to the bridge helps form an additional hydrogen 
bond to improve KAL-YZ0965 binding. Potential hydrogen bonds are represented 
with green lines. 
 
KAL-YZ0965, KAL-YZ0968, and KAL-YZ0970 together with KAL-55883121 
(similar and better binding affinity with KAL-21404358 in the MST assay) were 
thus selected for testing in the NanoBiT K-RasG12D–B-Raf interaction assay. We 
detected trends toward weaker luminescence signals in the presence of KAL-
YZ0965, KAL-YZ0968, and KAL-55883121 (Figure 3.10 and Figure 3.16). 
Moreover, KAL-YZ0965, KAL-YZ0968, and KAL-YZ0970 have improved aqueous 
solubility, which provides opportunities for future studies with these compounds 
(Figure 3.10 and Figure 3.16). 
 
KAL-11067146 docking pose in P110 site
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3.3 Conclusion and discussion 
K-RasG12D has been considered a challenging target over the past 30 years. Here, 
we explore a strategy for discovering small molecule inhibitors that directly bind 
to this oncogenic K-Ras mutant. This strategy started with computational design, 
leading to discovery of a potential binding pocket. The P110 site is in the 
allosteric lobe, which is opposite of the functional P loop (phosphate binding loop, 
residues 10–17), switch I (effector binding region, residues 30–40), and switch II 
(effector binding region and GEF and GAP binding region, residues 60–75) 
regions, which constitute the active site for GTP hydrolysis and interaction sites 
for effector proteins, including Raf, PI3K, RalGDS, and GAP (Figure 3.19)44, 
137. Despite the distance from the P110 site to effector domains, residues in 
switch I and switch II undergo conformational changes upon binding of KAL-
21404358, causing disruption of K-RasG12D signaling activity (Table 3.4). 
 



























The P110 site (orange) is in the allosteric lobe, opposite the functional P loop 
(blue), switch I (red), and switch II (green) domains that constitute the active site 
for GTP hydrolysis and effector protein binding. The left one shows the surface, 
whereas the right one shows the structure.  
 
Functional sites Residues 
P110 site 
Arg97, Asp105, Ser106, Glu107, Asp108, Val109, Pro110, 
Met111, Tyr 137, Gly138, Ile139, Glu162, Lys165, and His166. 
P-loop Gly10, Ala11, Asp12, Gly13, Val14, Gly15, Lys16, Ser17 
Switch I 
Asp30, Glu31, Tyr32, Asp33, Pro34, Thr35, Ile36, Glu37, Asp38, 
Ser39, Tyr40 
Switch II 
Gly60, Gln61, Glu62, Glu63, Tyr64, Ser65, Ala66, Met67, Arg68, 
Asp69, Gln70, Tyr71, Met72, Arg73, Thr74, Gly75, Glu76 
Allosterically affected 
with binding of KAL-
21404358 
Asp33, Ser39, Leu56, Gly60, Met67, Thr74 and Gly75 
Table 3.4 Residues in the P110 site, P loop, switch I, and switch II and those 
allosterically affected with binding of KAL-21404358. 
 
Key residues that undergo conformational changes upon binding are shown in 
bold. 
 
We used a tiered set of computational and biochemical assays to evaluate 
whether compounds can bind to this site and, if so, what effect they have on the 
K-RasG12D protein. The first-line screening consisted of computational ligand 
docking to select compounds predicted to bind in this site. The second screening 
filter involved the use of MST and TSA to validate binding to K-
RasG12D experimentally. The third tier was NMR line broadening and a HSQC 
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NMR binding assay to further discover the binding mode and location and to 
assess allosteric effects of binding. The fourth tier was a Ras functional assay 
involving direct interactions with Raf and two well-established cellular signaling 
pathways. 
 
KAL-21404358 was found to be the best candidate from this set of assays. KAL-
21404358 was further validated to specifically bind to K-RasG12D in the P110 site. 
Although the binding affinity was moderate, KAL-21404358 was able to disrupt 
the K-Ras–B-Raf interaction and Akt and Erk signaling pathways at high 
concentrations. GTP-bound K-RasG12D exists in two distinct conformations, state 
1 and state 2, where state 1 has a lower binding affinity for effectors34, 138, 139. On 
the basis of the experimental results, we hypothesize that KAL-21404358 binds 
to GTP-bound K-RasG12D state 1 and thus shifts the protein equilibrium from state 
2 toward state 1 (Figure 3.20). KAL-21404358 can also bind to the GDP-bound 
(inactive) conformation with a 2-fold lower affinity. We hypothesize that KAL-
21404358 stabilizes and traps K-RasG12D in this inactive GDP-bound state by 
reducing its probability to nucleotide exchange, thus decreasing the amount of 
GTP-bound K-RasG12D (Figure 3.20). Thus, the P110 pocket, according to this 
model, is slightly more pronounced in state 1 of the GTP-bound protein but is 
also present in the GDP-bound protein. 
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Figure 3.20 KAL-21404358 binding scheme.  
 
The orange ellipse represents inactive GTP-bound K-RasG12D (state 1). The 
green circle represents active GTP-bound K-RasG12D (state 2). The red ellipse 
represents inactive GDP-bound K-RasG12D. The size of the circles represents the 
relative amounts of different K-RasG12Dstates. In the absence of KAL-21404358, 
K-RasG12D favors the active state 2 conformation. When KAL-21404358 binds to 
GTP-bound K-RasG12D, it stabilizes state 1, disrupting the binding of effectors. 
When KAL-21404358 binds to GDP-bound K-RasG12D, it traps the protein in this 
inactive state, thereby reducing the amount of active-state protein. 
 
To optimize this scaffold, a high-resolution structure is likely needed. We 
attempted to obtain such a co-crystal structure without success, likely due to the 
low binding affinity and low solubility of KAL-21404358. Nonetheless, we did 
synthesize a series of analogues to define the structure–activity relationship and 
found that addition of a carbonyl group to the bridge enhances the binding affinity 
because of the formation of new hydrogen bonds and increase in the 
hydrophilicity of KAL-21404358. The binding affinities of those analogues were 
improved as shown by the MST assay, but their ability to disrupt K-Ras–B-Raf 
interaction was not enhanced. This remains to be studied further, especially by 




In summary, these findings suggest that the P110 site is a potential allosteric 
regulatory site for targeting oncogenic K-Ras proteins. KAL-21404358 is the first 
small molecule candidate for this site. This provides a new strategy for 




The KRASG12D plasmid was previously described55. Binding-deficient mutants of 
the KRASG12D plasmid were generated using a QuikChange XL site-directed 
mutagenesis kit. Primers were designed using the Agilent QuikChange Primer 
Design application and purchased from Integrated DNA Technologies: 
KRASG12DR97G forward primer, 5′ GAA GAT ATT CAC CAT TAT GGA GAA CAA 
ATT AAA AGA GTT AAG G 3′; KRASG12DR97G reverse primer, 5′ CTT AAC TCT 
TTT AAT TTG TTC TCC ATA ATG GTG AAT ATC TTC 3′; KRASG12DE107A 
forward primer, 5′ GAG TTA AGG ACT CTG CAG ATG TAC CTA TGG TCC 3′; 
KRASG12DE107A reverse primer, 5′ GGA CCA TAG GTA CAT CTG CAG AGT CCT 
TAA CTC 3′; KRASG12DD108A forward primer, 5′ TAA GGA CTC TGA AGCT GT 
ACC TAT GGT CC 3′; KRASG12DD108A reverse primer, 5′ ACC ATA GGT AC AGC 
T TCA GAG TCC TTA ACT C 3′; KRASG12DP110D forward primer, 5′ AGA TGT 
AGA TAT GGT CCT AG 3′; KRASG12DP110D reverse primer, 5′ AGG ACC ATA 
TCT ACA TCT TC 3′. DNA sequencing was performed to confirm the amino acid 
sequence of the construct (GeneWiz).  
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Protein Expression and Purification 
The KRASG12D construct was expressed in Escherichia coli BL21-Gold (DE3) 
cells (Stratagene). An isolated colony was transferred to 8 mL of LB medium with 
100 μg/mL ampicillin, and the inoculated culture was incubated while being 
shaken (225 rpm) at 37 °C for 4.5 h. The starter culture was added to 1 L of fresh 
LB medium with 100 μg/mL ampicillin. The culture was incubated while being 
shaken at 37 °C and 225 rpm until the OD600 reached 0.6. The temperature was 
then decreased to 15 °C. Cells were incubated with 500 μM isopropyl β-D-1- 
thiogalactopyranoside (IPTG) while being shaken at 15 °C and 225 rpm overnight. 
The next day, the bacteria were harvested by centrifugation at 4000g for 20 min 
at 4 °C and the pellet obtained was ready for purification or stored at −20 °C.  
The pellet was resuspended in 25 mL of chilled lysis buffer [10 mM Tris (pH 7.5), 
500 mM NaCl, 5 mM MgCl2, 5 mM imidazole, 2 mM TCEP, and Roche protease 
inhibitor cocktail]. The bacteria were lysed by sonication on ice for 6 min, and the 
lysate was centrifuged at 15000 rpm for 45 min at 4 °C to remove cell debris. The 
clarified lysate was incubated with Ni Sepharose 6 Fast Flow beads (GE Life 
Sciences) on a rotator at 4 °C for at least 1 h. The beads were washed with wash 
buffer [10 mM Tris (pH 7.5), 500 mM NaCl, 20 mM imidazole, 5 mM MgCl2, and 2 
mM TCEP] to remove nonspecific binding. The protein was eluted with 10 mM 
Tris (pH 7.5), 500 mM NaCl, 250 mM imidazole, 5 mM MgCl2, and 2 mM TCEP. 
The protein was further purified using a gel filtration Superdex 200 column in 
FPLC buffer containing 25 mM Tris (pH 7.5), 100 mM NaCl, 5 mM MgCl2, and 2 
mM TCEP. The fractions containing K-RasG12D were pooled together and 
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analyzed by sodium dodecyl sulfate−polyacrylamide gel electrophoresis 
(SDS−PAGE). The protein concentration was determined using absorbance at 
280 nm with an extinction coefficient of 11920 M−1 cm−1.  
 
Nucleotide Exchange 
Nucleotides in endogenous recombinant K-RasG12D were exchanged with GDP or 
GppNHp using an EDTA loading procedure. K-RasG12D protein (final 
concentration of 70 μM) was incubated with a 70-fold molar excess of EDTA 
(final concentration of 5 mM) and a 70-fold molar excess of new nucleotide (final 
concentration of 5 mM) for 2 h at 30 °C. After incubation, the sample was placed 
on ice for 2 min and then MgCl2 was added (final concentration of 65 mM) to stop 
the reaction. To remove excess unbound nucleotide, the sample was added to a 
NAP-5 column (GE Life Sciences) equilibrated with FPLC buffer and eluted with 
FPLC buffer at 100 μL per fraction. Eluted fractions were evaluated using the 
NanoDrop method to determine protein concentration.  
 
Microscale Thermophoresis (MST) 
One hundred microliters of 200 nM K-RasG12D was combined with 100 μL of 100 
nM RED-tris-NTA dye in PBS buffer with 3 mM DTT and 0.05% Tween 20 
(PBSTD buffer). The protein/dye mixture was incubated at room temperature for 
30 min, followed by centrifugation for 10 min at 4 °C and 15000g. The 
compounds were arrayed across a 16-point dilution series in PBSTD buffer and 
mixed in a 1:1 ratio with a labeled protein solution in a 20 μL volume. The 
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reaction mixture was loaded into standard treated capillaries and analyzed with 
Monolith NT.115 (Nanotemper Technologies) at 60% LED power and 40% MST 
power with a laser-on time of 5 s. The KD was calculated by taking the average of 
triplicate Fnorm measurements at each concentration and fitting the data to a 
sigmoidal four-parameter fitting function in Prism (GraphPad Software). R-Ras, 
R-Ras2, and Rap1A were purchased from ProSpecBio. K-Ras WT was 
purchased from Cell Biolabs. H-Ras WT was acquired from Enzo Life Sciences.  
 
Thermal Shift Assay (TSA) 
A fluorescent thermal shift assay was used to validate the binding and confirm 
the success of the nucleotide exchange procedure of all GTPases used in the 
study. The assay was carried out in triplicate in Fast 96-well optical plates 
containing 5 μM protein and 5× SYPRO Orange dye (Invitrogen) in a total volume 
of 20 μL/well. Samples were heated at a rate of 3 °C/min from 25 to 95 °C, and 
protein unfolding was observed by monitoring the fluorescence of SYPRO 
Orange dye at 470 nm excitation and 623 nm emission using a ViiA7 real-time 
polymerase chain reaction machine (Applied Biosystems). K-RasG12D with 
dimethyl sulfoxide (DMSO) was used on the same plate as a reference for the 
shift in melting temperature (Tm) with compounds. Each GTPase with an 
endogenous nucleotide was also used on the same plate as a reference for the 
shift in melting temperature (Tm) with the new nucleotide. All experiments were 
performed in triplicate. Data were analyzed using Protein Thermal Shift Software 
(Applied Biosystems) to determine the Tm of each well.  
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NMR Line Broadening 
For NMR line broadening studies, the samples were buffer exchanged into Milli-
Q water using a Millipore spin column (13000g for 5 min at 4 °C, repeated five 
times, each time adding fresh Milli-Q water and discarding the flow-through). 
Then, 10% D2O was added to the protein/ compound mixtures: protein only, 1:1, 
1:3, and compound only. NMR line broadening experiments were performed on 
Bruker Avance III 500 Ascend (500 MHz) spectrometers (Columbia University) at 




Uniformly 15N-labeled K-RasG12D protein without an N-terminal His6 tag was 
prepared. The KRASG12D construct was expressed in E. coli BL21-Gold (DE3) 
cells (Stratagene) growing at 37 °C in M9 minimal medium supplemented with 
100 μg/mL ampicillin, 2 mM MgSO4, 100 mM CaCl2, 1× trace metals, 1× RPMI 
1640 vitamin stock (Sigma-Aldrich, catalog no. R7256), 10 μg/mL biotin, 10 μg/ 
mL thiamine hydrochloride, and 3 g/L 15NH4Cl as the sole nitrogen source. The 
remaining steps were identical to K- RasG12D expression and purification 
described above. Thrombin was then added at a level of 5 units/mg of protein to 
cleave the N-terminal His6 tag. The reaction was allowed to proceed overnight at 
4 °C. The next day, the protein solution was passed over Ni-Sepharose 6 Fast 
Flow beads (GE Life Sciences) and the flow-through containing the 15N-labeled 
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K- RasG12D protein without a histidine tag was concentrated and flash-frozen. The 
purity was checked by SDS−PAGE.  
 
1H−15N HSQC experiments were performed on Bruker Avance III 500 Ascend 
(500 MHz) spectrometers (Columbia University) at 298 K. Uniformly 15N-labeled 
K-RasG12D was dissolved at concentrations of 100−150 μM in NMR buffer [50 
mM HEPES (pH 7.4), 50 mM NaCl, 2 mM MgCl2, 2 mM TCEP, and 10% D2O]. 
The 1H carrier frequency was positioned at the water resonance. The 15N carrier 
frequency was positioned at 115 ppm. Suppression of the water signal was 
accomplished using the WATERGATE sequence. Heteronuclear decoupling was 
accomplished using the GARP decoupling scheme. Assignments of K-RasG12D 
were previously published55. All data were processed and analyzed using 
TopSpin 3.1 (Bruker) and Sparky (developed by T. D. Goddard and D. G. Kneller, 
University of California, San Francisco, CA).  
 
NanoBiT Split Luciferase Assay 
HEK293T cells from ATCC (catalog no. CRL-1573) were seeded 16 h prior to 
use in 10% fetal bovine serum (FBS) in Dulbecco’s modified Eagle’s medium. 
Plasmids (KRAS-SmBiT/BRAF-LgBiT or SmBiT/LgBiT positive controls) were 
transfected into HEK293T cells and incubated for 48−72 h. After transfection was 
complete, compounds with the indicated concentration were added and treated 
for 1 h at 37 °C and 5% CO2. Plates were then read with a Tecan Infinite M200 
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plate reader for luminescence every 6 min for 3 h at 37 °C. Data were analyzed 
using Prism 7.0 (GraphPad Software).  
 
Cell-Based K-RasG12D−Raf RBD Pull Down 
LS513 cells from ATCC (catalog no. CRL-2134) were seeded 16 h prior to use in 
10% FBS in RPMI-1640. The medium was then aspirated and replaced with 
serum-free medium containing KAL-21404358, and cells were incubated for 24 h. 
The medium was removed, washed with cold PBS, lysed, and spun down at 
13000 rpm at 4 °C to remove unlysed cells and debris. The lysate was incubated 
with Raf-1 RBD agarose beads (EMD Millipore) for 2 h with rotation at 4 °C. The 
solution was then spun down at 1500g, and the supernatant removed. The beads 
were washed twice with PBS, resuspended in 4× SDS, and then analyzed by the 
Western blotting procedure detailed below.  
 
Western Blots 
LS513 cells were seeded in RPMI-1640 and 10% FBS with 1% penicillin and 
streptomycin (PS) 16 h prior to use. The medium was then aspirated, and 
compounds were added as solutions in serum-free medium (RPMI-1640 with 1% 
PS) at the indicated concentration. Following treatment, the medium was 
aspirated from each dish and cells were washed twice with PBS. Cells were 
lysed with 70 μL of lysis buffer (RIPA buffer from ThermoFisher, catalog no. 
89900, 1 mM EDTA, 1 mM phenylmethanesulfonyl fluoride, 1× Halt protease 
inhibitor cocktail from ThermoFisher, catalog no. 78430, and 1× Halt 
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phosphatase inhibitor cocktail from ThermoFisher, catalog no. 78426). Unlysed 
cells and debris were pelleted for 15 min at 16000g and 4 °C. Samples were 
separated using SDS−PAGE and transferred to a polyvinylidene difluoride 
membrane. The transfer was performed using the iBlot2 system (Invitrogen). 
Membranes were treated with Li-COR Odyssey blocking buffer for at least 1 h at 
room temperature and then incubated with a primary antibody (1:1000) in a 1:1 
solution of PBS-T (PBS with 0.1% Tween 20) and Li-COR odyssey blocking 
buffer overnight at 4 °C. Following three 5 min washes in PBS-T, the membrane 
was incubated with secondary antibodies (1:3000) in a 1:1 solution of PBS-T and 
Li-COR Odyssey blocking buffer for 1 h at room temperature. Following three 5 
min washes in PBS-T, the membrane was scanned using the Li-COR Odyssey 
Imaging System. Antibodies for pErk1/2, Erk1/2, pAkt Ser473, Akt, pan-Ras (Cell 
Signaling), and Raf-1 (Santa Cruz) were detected using a goat anti-rabbit or goat 
anti- mouse IgG antibody conjugated to an IRdye at 800CW and 680CW, 
respectively (Li-COR Biosciences).  
 
Synthesis of KAL-21404358 analogs 
General Methods 
Starting materials were purchased form Sigma-Aldrich, Fisher Scientific, Ark 
Pharm, Oakwood Chemical, Cambridge Isotope Laboratory, or AK Scientific and 
were used as received unless stated otherwise. All solvents were reagent grade. 
Column chromatography was performed on a Teledyne ISCO CombiFlash® Rf+ 
using RediSep® Normal-phase silica flash columns. Thin layer chromatography 
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(TLC) was performed on Silicycle SiliaPlate™ Glass TLC Plates (250 µm, 20 x 
20 cm). 1H NMR spectra were recorded at ambient temperature using 300 MHz, 
400 MHz, or 500 MHz spectrometers (Bruker DPX) as indicated. Chemical shifts 
are reported in ppm relative to the residual solvent peaks (1H NMR: DMSO-d6, δ 
2.50; chloroform-d, δ 7.26; methanol-d4, δ 3.31). The following abbreviations are 
used to indicate multiplicity: s (singlet), d (doublet), t (triplet), q (quartet), hept 
(heptuplet), m (multiplet), br (broad). High resolution mass spectra (HRMS) were 
acquired on a time-of-flight spectrometer with atmospheric pressure chemical 
ionization (APCI) or electrospray ionization (ESI), as indicated, and were 
obtained by peak matching. All reactions were run under an atmosphere of 
nitrogen or argon in glassware that was flame-dried under argon unless 
otherwise stated. Aqueous solutions were prepared from nanopure water with a 
resistivity over 18 MΩ·cm. Unless otherwise noted, all reagents were 
commercially available. 
Abbreviations: HOBT = hydroxybenzotriazole, EDC = 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide, DCM = dichloromethane, MeOH = methanol, 
HCl = hydrochloric acid, Na2SO4 = sodium sulfate, DMF = N,N-
dimethylformamide, THF = tetrahydrofuran, rt = room temperature. 
 
General experimental procedures for the synthesis of KAL-YZ0960 - KAL-
YZ0979 
 89 
Method I: Carboxylic acid (1.0 equiv.), amine (2.0 equiv.), HOBT (2.0 equiv.), 
and EDCHCl (2.0 equiv.) were dissolved in anhydrous THF (0.17 M). The 
reaction was performed under N2 and stirred overnight. The reaction mixture was 
washed with saturated sodium chloride twice. The organic layer was dried with 
anhydrous Na2SO4, and concentrated. The crude product was purified by 
CombiFlash (Teledyne ISCO) 0-10% MeOH/DCM first then by prep HPLC 0-90% 
acetonitrile/water.  
Method II: Carboxylic acid (1.0 equiv.), amine (1.5 equiv.), HOBT (1.5 equiv.), 
EDCHCl (1.5 equiv.), and N-ethyldiisopropylamine (1.5 equiv.) were dissolved in 
anhydrous DMF (0.17 M). The reaction mixture was stirred in microwave reactor 
at 130°C for 10 min. The organic solvent was evaporated. The crude product was 




1H NMR (400 MHz, chloroform-d) δ 12.53 (s, 1H), 8.21 (dd, J = 8.0, 1.6 Hz, 1H), 
7.76 (ddd, J = 8.7, 7.1, 1.7 Hz, 1H), 7.60 (dd, J = 8.7, 1.0 Hz, 1H), 7.47 (ddd, J = 
8.1, 7.1, 1.0 Hz, 1H), 7.16 (s, 1H), 4.06 – 3.94 (m, 6H), 3.68 (s, 2H), 3.43 (dd, J = 














1H NMR (400 MHz, chloroform-d) δ 9.67 (d, J = 6.2 Hz, 1H), 8.34 – 8.20 (m, 2H), 
7.89 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.78 (s, 1H), 7.70 (ddd, J = 8.2, 6.9, 1.1 Hz, 
1H), 4.27 (s, 3H), 4.00 (q, J = 5.9, 5.0 Hz, 6H), 3.82 (s, 2H), 3.54 – 3.46 (m, 2H), 
3.00 (s, 2H). 
MS (APCI+, m/z): [M+H]+ cald for C17H22N3O3, 316.16, found 316.2 
 
KAL-YZ0963: 6-methyl-N-(2-morpholinoethyl)picolinamide 
1H NMR (400 MHz, chloroform-d) δ 8.70 (s, 1H), 7.95 (d, J = 7.6 Hz, 1H), 7.74 (t, 
J = 7.7 Hz, 1H), 7.32 (dd, J = 7.8, 1.0 Hz, 1H), 4.03 – 3.89 (m, 6H), 3.87 – 3.54 
(m, 2H), 3.40 (t, J = 6.1 Hz, 2H), 2.96 (s, 2H), 2.58 (s, 3H) 



















1H NMR (400 MHz, chloroform-d) δ 9.11 (s, 1H), 8.42 (d, J = 5.9 Hz, 1H), 7.76 (d, 
J = 2.6 Hz, 1H), 7.03 (dd, J = 5.9, 2.6 Hz, 1H), 5.32 (s, 1H), 4.14 – 3.89 (m, 9H), 
3.86 – 3.55 (m, 2H), 3.42 (t, J = 5.8 Hz, 2H), 2.97 (s, 2H). 
MS (APCI+, m/z): [M+H]+ cald for C13H20N3O3, 266.15, found 266.1 
 
KAL-YZ0966: (4-hydroxyquinolin-2-yl)(4-isopropylpiperazin-1-yl)methanone 
1H NMR (400 MHz, Chloroform-d) δ 8.31 (dt, J = 8.1, 1.1 Hz, 1H), 7.73 – 7.63 (m, 
2H), 7.42 (ddd, J = 8.1, 5.2, 2.9 Hz, 1H), 6.38 (s, 1H), 3.87 (d, J = 44.4 Hz, 4H), 
3.42 (td, J = 13.2, 6.6 Hz, 1H), 3.21 (s, 4H), 1.33 (d, J = 6.6 Hz, 6H). 
























1H NMR (400 MHz, Chloroform-d) δ 8.26 (dd, J = 8.2, 1.4 Hz, 1H), 7.72 (d, J = 
8.4 Hz, 1H), 7.61 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.35 (t, J = 7.4 Hz, 1H), 6.36 (s, 
1H), 4.08 – 3.61 (m, 4H), 3.34 – 3.27 (m, 4H), 1.37 (s, 9H). 




1H NMR (500 MHz, DMSO-d6) δ 8.11 (d, J = 7.9 Hz, 1H), 7.73 (t, J = 7.4 Hz, 1H), 
7.64 (d, J = 8.3 Hz, 1H), 7.42 (t, J = 7.5 Hz, 1H), 6.27 (s, 1H), 3.88 – 3.82 (m, 2H), 
3.74 – 3.64 (m, 4H), 3.23 – 3.16 (m, 2H), 3.16 (s, 2H), 3.07 (t, J = 5.4 Hz, 2H). 

















1H NMR (400 MHz, chloroform-d) δ 8.32 – 8.25 (m, 1H), 7.72 – 7.60 (m, 2H), 
7.38 (ddd, J = 8.1, 6.6, 1.4 Hz, 1H), 6.37 (s, 1H), 3.87 (s, 4H), 3.26 (s, 4H), 2.85 
(d, J = 7.2 Hz, 3H), 1.02 (dt, J = 7.7, 2.9 Hz, 1H), 0.75 – 0.65 (m, 2H), 0.35 – 
0.28 (m, 2H). 
MS (APCI+, m/z): [M+H]+ cald for C18H22N3O2, 312.16, found 312.5 
 
KAL-YZ0970: [1,4'-bipiperidin]-1'-yl(4-hydroxyquinolin-2-yl)methanone 
1H NMR (400 MHz, Chloroform-d) δ 11.73 (s, 1H), 8.36 – 8.29 (m, 1H), 7.72 – 
7.60 (m, 2H), 7.39 (ddd, J = 8.1, 6.3, 1.8 Hz, 1H), 6.30 (s, 1H), 4.71 (s, 1H), 3.97 
(d, J = 46.1 Hz, 1H), 3.51 (s, 2H), 3.40 – 3.24 (m, 1H), 3.14 (s, 1H), 2.66 (d, J = 
20.4 Hz, 3H), 1.98 (d, J = 51.6 Hz, 8H), 1.53 – 1.33 (m, 1H), 1.28 (s, 1H). 
















1H NMR (400 MHz, chloroform-d) δ 8.34 (t, J = 6.4 Hz, 3H), 7.76 – 7.64 (m, 2H), 
7.44 (ddd, J = 8.2, 6.5, 1.5 Hz, 1H), 6.73 (s, 1H), 6.59 (t, J = 4.8 Hz, 1H), 5.09 (s, 
4H), 3.91 (s, 4H), 3.77 (d, J = 5.7 Hz, 4H). 




1H NMR (400 MHz, Methanol-d4) δ 7.72 (d, J = 8.3 Hz, 1H), 7.35 – 7.24 (m, 1H), 
7.17 (d, J = 7.7 Hz, 1H), 6.39 (s, 1H), 4.04 (s, 2H), 3.88 (t, J = 5.5 Hz, 2H), 3.79 
(s, 3H), 3.29 (d, J = 16.1 Hz, 4H), 3.19 (t, J = 5.6 Hz, 2H). 
MS (APCI+, m/z): [M+H]+ cald for C16H20N3O4, 318.14, found 318.8 
 
KAL-YZ0975: 2-(4-(2-hydroxyethyl)piperazine-1-carbonyl)quinolin-4(1H)-one 
1H NMR (500 MHz, DMSO-d6) δ 8.03 (d, J = 7.8 Hz, 1H), 7.88 – 7.81 (m, 1H), 
7.65 (d, J = 8.4 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 6.62 (s, 1H), 3.86 (s, 4H), 3.75 (t, 



















1H NMR (400 MHz, Chloroform-d) δ 8.24 (dd, J = 8.3, 1.4 Hz, 1H), 7.97 (d, J = 
8.4 Hz, 1H), 7.76 (ddd, J = 8.4, 6.8, 1.5 Hz, 1H), 7.60 (ddd, J = 8.2, 6.9, 1.2 Hz, 
1H), 7.17 (s, 1H), 6.03 (s, 1H), 4.11 (s, 3H), 4.09 – 3.99 (m, 3H), 3.48 (d, J = 8.1 
Hz, 4H), 3.30 – 3.22 (m, 2H). 





1H NMR (400 MHz, Chloroform-d) δ 7.72 (t, J = 7.7 Hz, 1H), 7.53 (d, J = 7.7 Hz, 
1H), 7.24 (s, 0H), 5.58 (s, 1H), 4.10 – 4.06 (m, 4H), 4.00 (t, J = 5.0 Hz, 2H), 3.38 
















1H NMR (400 MHz, Chloroform-d) δ 8.38 (d, J = 5.8 Hz, 1H), 7.30 (d, J = 2.6 Hz, 
1H), 6.99 – 6.90 (m, 1H), 4.12 (s, 4H), 4.08 – 4.01 (m, 2H), 3.93 (s, 3H), 3.43 (s, 
4H), 3.26 – 3.10 (m, 2H). 
MS (APCI+, m/z): [M+H]+ cald for C13H19N3O3, 266.14, found 266.4 
Synthesis of KAL-PHB6001 
 
2-(4-Methylpiperazine-1-carbonyl)-1,4-dihydroquinolin-4-one (KAL-
PHB6001): To a suspension of kynurenic acid (1.0 mmol, 1.0 eq, 189 mg) in THF 
(6 mL) at room temperature was added HOBTHCl (1.5 mmol, 1.5 eq, 203 mg), 








150 mg, 166 µL) subsequently and the mixture was stirred at room temperature 
overnight. The solvent was evaporated in vacuo and the crude product purified 
by preparative RP-HPLC to give the product (125 mg, 46% yield). Procedure 
analogous to Cincinelli et al., Tetrahedron, 70, 2014, 9797-9804. 1H NMR (400 
MHz, Methanol-d4) δ 8.26 (ddd, J = 8.2, 1.5, 0.6 Hz, 1H), 7.76 (tdd, J = 9.2, 7.6, 
1.3 Hz, 1H), 7.68 (ddd, J = 8.4, 1.2, 0.6 Hz, 1H), 7.53 – 7.42 (m, 1H), 6.45 (s, 1H), 
3.93 (s, 4H), 3.40 (s, 4H), 2.97 (s, 3H). MS (APCI+, m/z): C15H18N3O2 [M+H]+: 
272.1.  
Synthesis of KAL-PHB6002 
 
4-Oxo-N-[2-(piperidin-1-yl)ethyl]-1,4-dihydroquinoline-2-carboxamide (KAL-
PHB6002: To a suspension of kynurenic acid (1.0 mmol, 1.0 eq, 189 mg) in THF 
(6 mL) at room temperature was added HOBTHCl (1.5 mmol, 1.5 eq, 203 mg), 
EDCHCl (1.5 mmol, 1.5 eq, 288 mg) and 1-(2-aminoethyl)piperidine (1.5 mmol, 
1.5 eq, 192 mg, 214 µL) subsequently and the mixture was stirred at room 
temperature overnight. The solvent was evaporated in vacuo and the product 
triturated upon addition of water. The resulting suspension was filtered and the 
product was isolated as a colorless solid (147 mg, 49% yield). 1H NMR (400 MHz, 
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DMSO-d6) δ 8.90 (s, 1H), 8.08 (d, J = 8.1 Hz, 1H), 7.98 – 7.89 (m, 1H), 7.69 (t, J 
= 7.7 Hz, 1H), 7.37 (s, 1H), 6.73 (s, 1H), 3.32 (s, 4H), 2.45 – 2.37 (m, 4H), 1.56 – 
1.45 (m, 4H), 1.44 – 1.32 (m, 2H). MS (APCI+, m/z): C17H22N3O2 [M+H]+: 300.2.  
Synthesis of KAL-PHB6003 
 
N-[2-(Morpholin-4-yl)ethyl]-4-oxo-1,4-dihydroquinoline-2-carboxamide (KAL-
PHB6003): To a suspension of kynurenic acid (1.0 mmol, 1.0 eq, 189 mg) in THF 
(6 mL) at room temperature was added HOBTHCl (1.5 mmol, 1.5 eq, 203 mg), 
EDCHCl (1.5 mmol, 1.5 eq, 288 mg) and 4-(2-aminoethyl)morpholine (1.5 mmol, 
1.5 eq, 195 mg, 197 µL) subsequently and the mixture was stirred at room 
temperature overnight. The solvent was evaporated in vacuo and the product 
triturated upon addition of water. The resulting suspension was filtered and the 
product was isolated as a colorless solid (59 mg, 20% yield). 1H NMR (400 MHz, 
DMSO-d6) δ 11.78 (s, 1H), 8.94 (s, 1H), 8.07 (d, J = 8.0 Hz, 1H), 7.94 (d, J = 8.4 
Hz, 1H), 7.73 – 7.59 (m, 1H), 7.45 – 7.18 (m, 1H), 6.68 (s, 1H), 3.58 (t, J = 4.6 Hz, 
4H), 3.44 (q, J = 6.4 Hz, 2H), 2.43 (t, J = 4.7 Hz, 4H). MS (APCI+, m/z): 
C16H20N3O3 [M+H]+: 302.0.  
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Chapter 4 Generation, phenotypic screen and identification of ferroptotic 
antibodies 
4.1 Introduction 
In this chapter, I will talk about the strategy we used to find a ferroptosis antibody 
marker. We first produced an untargeted pool of monoclonal antibodies from the 
spleens of mice that were challenged with the membrane fractions of cells 
induced to undergo ferroptosis with the system xc- inhibitor and erastin analog 
known as piperazine erastin (PE). Approximately 4,750 antibodies were 
generated. We used C11-BODIPY as the first screener and 672 hits were 
selected. Then we screened 672 monoclonal antibodies by immunofluorescence, 
through which three antibodies stood out. The 3F3 anti-ferroptotic membrane 
antibody (3F3 FMA) worked well in a third-round screen of the three hits on a 
larger scale by immunofluorescence. We validated the selectivity of 3F3 FMA by 
treating the cells with various ferroptosis inducers and inhibitors as well as 
apoptosis inducers. We also tested the 3F3 FMA in several cancer cell lines. In 
addition, we identified the antigen of 3F3 FMA as transferrin receptor protein 1 
(TfR1) by immunoprecipitation-mass spectrometry (IP-MS). TfR1 imports iron 
from the extracellular environment into cells, contributing to the cellular iron pool 
required for ferroptosis114. We found that 3F3 FMA was located at the plasma 
membrane and the Golgi by co-localization with organelle markers. 
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4.2 Results 
4.2.1 Generation of PE-induced membrane fractions and purification of 
antibodies 
To identify a reliable and specific ferroptosis marker, we started with generation 
of an untargeted pool of monoclonal antibodies, by infecting mice with ferroptotic 
membrane fractions. Suspension OCI-LY7 cells were incubated with PE, a class 
1 ferroptosis inducer, for 19 hours at 37 ˚C. The increase of lipid peroxides 
confirmed by fluorescent changes of C11-BODIPY was used as a sign of 
ferroptotic process (Figure 4.1). Then the ferroptotic cells were lysed, 
homogenized, and centrifuged to obtain purified total membrane and plasma 
membrane fractions (see materials and experimental details). The purified total 
membrane and plasma membrane were confirmed using organelle markers by 
western blot (Figure 4.2).  
 
Figure 4.1 Cells were confirmed to be undergoing ferroptosis by fluorescent 
probe C11-BODIPY as a lipid ROS indicator.  
 
Blue represents DMSO-treated cells. Red represents PE-treated cells. 
DMSO
5 μM PE  
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Figure 4.2 Western blot confirmation of plasma membrane and total membrane 
by organelle markers.  
 
The presence of plasma membrane was determined by anti-sodium potassium 
ATPase antibody, cytosol by anti-GAPDH, ER by anti-PDI and nuclei by anti-
Histone H3. 
 
Female 20-week-old mice were immunized with ferroptotic membrane fractions. 
Following a 12-week boosting protocol, splenocytes were isolated and 
electrofused with a myeloma fusion partner generate hybridoma cells140. ~4,750 
antibodies to unknown targets were purified. 
 
4.2.2 Phenotypic screen of ferroptotic antibodies by flow cytometry and 
immunofluorescence 
~4,750 antibodies to unknown targets were tested in a phenotypic high-
throughput screen (Figure 4.3). 672 antibodies showed increased intensities in 
IKE-treated cells by flow cytometry. 156 antibodies showed increased 












































were validated through visual inspection to remove false positives. Three hits 
stood out by picking cells with more than three bright spots in the cytoplasm or 
overall higher cytoplasmic intensity over five replicates. Image analysis of 3F3 
FMA is shown as an example (Figure 4.4 and Figure 4.5). 
 
Figure 4.3 A flow chart illustrating the screen from ~4,750 unknown target 







in RSL3 > DMSO
71 hits
cherry picking and 
high-content-analysis:
% cells with > 3 spots
and/or fluorescence intensity
















Figure 4.4 3F3 FMA is shown as an example of cherry picking and high-content-
analysis. 
 
There was increased number of cells, which had more than three spots in 
cytoplasm in RSL3-induced ferroptosis.  * indicated p value ≤ 0.05. Data plotted 


































Figure 4.5 High-content analysis sequence of 3F3 FMA as an example. 
 
A. The first step was to select cell population by finding nuclei and cytoplasm 
without border cells and small cells. Green cells in graph 6 were valid cells for 
calculation. 
 
B. Cells with more than 3 spots within cytoplasm were picked. Green cells in 
graph 3 were positive selection.  
1. Input image 2. Find nuclei 3. Find cytoplasm
5. Remove border objects 6. Remove small cells4. Select cell region (cytoplasm)
A. Select cell population for further analyses in B
1. Calculate cytoplasm intensity 2. Count spots within cytoplasm 3. Output: cells with > 3 spots
B. Calculate properties
=> green: positive selection
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4.2.3 3F3 FMA can be used as a ferroptosis marker by immunofluorescence 
We verified the three hits in a larger scale by IF using confocal microscopy. We 
used RSL3 as the first screen, because it’s the most potent inducer requiring low 
concentration and short incubation time. 30% of HT-1080 cells died after 4 h 
incubation of 1 μM RSL3. Later we used > 30% dying cells as an indicator of 
ferroptosis ongoing. 3F3 FMA was the only Ab showing differences in RSL3-
induced ferroptosis. Under ferroptosis, 3F3 FMA stained cell boundaries and the 
inside puncta became brighter (Figure 4.6). To further validate the 3F3 FMA, we 
added ferroptosis inhibitor Fer-1 together with RSL3 (Figure 4.6) or IKE (Figure 
4.7). The 3F3 FMA didn’t show any different staining patterns in Fer-1 treated 
groups compared to DMSO treated groups. Quantification of the membrane 
fluorescence intensities was shown to highlight the difference. 
 
Figure 4.6 3F3 FMA showed increased intensities in plasma membrane in RSL3-
induced ferroptosis 
 
HT-1080 cells (human fibrosarcoma cells) were incubated with 1 μM RSL3 or 1 
μM RSL3 + 5 μM Fer-1 for 4 h. 3F3 FMA showed significant different pattern in 
RSL3-induced ferroptosis, but not in Fer-1 rescued process. Nuclei were stained 
with DAPI in blue. 3F3 FMA was stained with Alexa Fluor 594 in red. White 
arrows indicated the differences. Quantification of membrane intensities of 3F3 
FMA was shown on the right (DMSO, n = 107; RSL3, n = 96; RSL3 + Fer-1 n = 
123). **** indicated p value ≤ 0.0001, ns indicated p value > 0.05 (one-way 




Figure 4.7 3F3 FMA showed increased intensities in plasma membrane in IKE-
induced ferroptosis 
 
HT-1080 cells were incubated with 10 μM IKE and 5 μM Fer-1 for 8 h. Nuclei 
were stained with DAPI in blue. 3F3 FMA was stained with Alexa Fluor 594 in red. 
3F3 FMA showed significant different pattern in IKE-induced ferroptosis, but not 
in Fer-1 rescued process. White arrows indicated the differences. Quantification 
of membrane intensities of 3F3 FMA was shown on the bottom (DMSO, n = 68; 
IKE, n = 145; IKE + Fer-1, n = 98). **** indicated p value ≤ 0.0001, ns indicated p 
value > 0.05 (one-way ANOVA). Data plotted are mean ± s.e.m. Each dot 
represents one cell. 
 
We then used various ferroptosis inducers – IKE, erastin, FIN56, FINO2 and 
tBuOOH. Same changes of 3F3 FMA pattern were observed (Figure 4.8) 
 
Figure 4.8 3F3 FMA showed increased intensities in plasma membrane in 
ferroptosis 
 
HT-1080 cells (human fibrosarcoma cells) were incubated with 10 μM IKE for 8 h, 
15 μM erastin for 8 h, 10 μM FIN56 for 8 h. 15 μM FINO2 for 8 h and 100 μM 
tBuOOH for 8 h. 3F3 FMA showed different staining pattern in IKE, erastin, 
FIN56, FINO2 and tBuOOH-induced ferroptosis. Nuclei were stained with DAPI 
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in blue. 3F3 FMA was stained with Alexa Fluor 594 in red. White arrows indicated 
the differences. Quantification of membrane intensities of 3F3 FMA was shown 
on the bottom (IKE, n = 113 and 129; erastin, n= 68 and 92; FIN56, n= 68 and 86; 
FINO2, n = 59 and 30; tBuOOH, n = 73 and 49). **** indicated p value ≤ 0.0001 
(two-tailed t-test). Data plotted are mean ± s.e.m. Each dot represents one cell. 
 
To test whether 3F3 FMA had different patterns in apoptosis to thereby 
differentiate ferroptosis from apoptosis, we used staurosporine (STS) to induce 
apoptosis and cleaved caspase-3 antibody as a marker of apoptosis. 
Accumulation of 3F3 FMA on the cell surface wasn’t detected, indicating that the 
pattern change of 3F3 FMA was specific to ferroptosis (Figure 4.9). To further 
test the ferroptosis specificity of 3F3 FMA, camptothecin (CPT) was also used to 
induce apoptosis in HT-1080 cells, with cleaved PARP antibody as an apoptosis 
marker. Similar to the STS-treated cells, there was no significant increase in 3F3 
FMA accumulation on the cell surface, further indicating that this accumulation 
pattern is specific to ferroptosis. 
 
Figure 4.9 3F3 FMA showed decreased intensities in plasma membrane in 
apoptosis 
 
HT-1080 cells (human fibrosarcoma cells) were incubated with 1 μM 
staurosporine (STS) for 6 h and 2 μM camptothecin for 24 h. Cleaved caspase-3 
antibody and cleaved PARP antibody were used to mark the initiation of 
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apoptosis. The stain pattern of 3F3 FMA in apoptosis was different from the one 
in ferroptosis. Nuclei were stained with DAPI in blue. 3F3 FMA was stained with 
Alexa Fluor 594 in red. Quantification of membrane intensity of 3F3 FMA (DMSO, 
n = 71, STS, n = 53; DMSO, n = 166, camptothecin, n = 91) and overall intensity 
of cleaved caspase-3 (n = 7) and cleaved PARP (n = 7) is shown on the right. * 
indicated p value ≤ 0.05, *** indicated p value ≤ 0.001. Data plotted are mean ± 
s.e.m. Each dot represents one cell. 
 
Next, we expanded the validation to other cancer cell lines. We picked A-673 
(human muscle sarcoma cells), SK-BR-3 (human breast cancer cells), Huh7 
(hepatocyte-derived carcinoma cells) and SK-LMS-1 (human leiomyosarcoma 
cells) which were all sensitive to ferroptosis. Again, we found that 3F3 FMA 
concentrated in cell boundaries and became brighter (Figure 4.10). Quantification 
of membrane fluorescence intensities was shown on the right. Taking all the data 
together, we found that the 3F3 FMA could be used as a ferroptosis marker in IF.  
 
Figure 4.10 3F3 FMA worked in A-673, SK-BR-3, Huh-7 and SK-LMS-1 cells 
 
A-673 cells, SK-BR-3 cells, Huh-7 cells and SK-LMS-1 cells were incubated with 
1 μM RSL3 for 4 h. Same pattern change of 3F3 FMA were observed. Nuclei 
were stained with DAPI in blue. 3F3 FMA was stained with Alexa Fluor 594 in red. 
White arrows indicated the differences. Quantification of membrane intensities of 
3F3 FMA was shown on the right (A-673, n = 70 and 16; SK-BR-3, n = 65 and 33; 
Huh-7, n = 63 and 61; SK-LMS-1, n = 149 and 139). **** indicated p value ≤ 




Similar to apoptosis, nuclear shrinkage under ferroptosis was found with a 17% 
decrease (Figure 4.11). We validated this finding by IF in large scale (Figure 
4.12). The extent of shrinkage depended on the kind of inducers and incubation 
time. The nuclei shrank by 27% in 4 h incubation of 1 μM RSL3, 12% in 8 h 
incubation of 10 μM IKE, 21% in 8 h incubation of 15 μM erastin, 17% in 8 h 
incubation of 10 μM FIN56 and 49% in 8 h incubation of 15 μM FINO2. This 
provides another morphological feature of ferroptosis. 
 
Figure 4.11 Nuclei shrank in ferroptotic cells 
 
HT-1080 cells in plates 1-3 were treated with DMSO and cells in plates 4-6 were 
treated with RSL3. Nucleus areas were identified and measured. The average 
nucleus area for DMSO group is 240 μm2 while the ones for RSL3 group is 200 
μm2 with a decrease of 17%. 
 
Plates 1-3 with DMSO





Figure 4.12 Nuclei shrank in ferroptotic cells induced by different ferroptosis 
inducers 
 
HT-1080 cells were incubated with 1 μM RSL3, 10 μM IKE for 8 h, 15 μM erastin 
for 8 h, 10 μM FIN56 for 8 h and 15 μM FINO2 for 8 h. Nuclei were stained by 
DAPI and identified using CellProfiler 3.1.8. Mean areas of nuclei for each cell 
were then calculated. Quantification of nucleus area was shown (DMSO, n = 107; 
RSL3, n = 96; DMSO, n = 113, IKE, n = 129; DMSO, n = 68, erastin, n = 92; 
DMSO, n = 68, FIN56, n = 86; DMSO, n = 59, FINO2, n = 30). NuleaData plotted 
are mean ± s.e.m. The nuclei shrank by 27% in 4 h incubation of 1 μM RSL3, 12% 
in 8 h incubation of 10 μM IKE, 21% in 8 h incubation of 15 μM erastin, 17% in 8 
h incubation of 10 μM FIN56 and 49% in 8 h incubation of 15 μM FINO2. 
 
4.2.4 Antigen identification of 3F3 FMA 
Next, we aimed to identify the antigen of 3F3 FMA. The identification of the target 
not only could help further validate the antibody, but also help increase the 
understanding of the mechanisms of ferroptosis. We used immunoprecipitation 
mass spectrometry (IP-MS). First, we incubated 3F3 FMA with a cell lysate 

































































































































bound to the beads. Then we analyzed the beads by mass spectrometry. 
Transferrin receptor protein 1 had the highest probability at 63% with 32 
exclusive unique peptides, 48 exclusive unique spectra and 53% amino acids 
coverage (Figure 4.13).  
 
Figure 4.13 IP-MS result of human TfR1 sequence. 
 
The yellow shades represented the identified sequence. Green shades were 
modified amino acids (M: oxidation of methionine and N: deamination of 
asparagine). The sequence coverage was 53%. 
 
We further validated the antigen by siRNA knockdown assay. siRNAs of TfR1 
and NT (non-target) were transfected in HT-1080 cells and incubated for 48 h. 
Additional 24 h later, cells were fixed and stained for 3F3 FMA and nuclei. In 
siTfR1 group, there wasn’t any fluorescence of 3F3 FMA, supporting the 
argument that the target was transferrin receptor protein 1 (Figure 4.14).   
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Figure 4.14 3F3 FMA didn’t have any signals in siRNA knockdown of TfR1 
 
10 μM of siTfR1 and siNT were combined with Lipofectamine RNAiMAX in Opti-
Mem media for 48 h. Then, HT-1080 cells were reseeded in regular media for 
additional 24 h. Cells were incubated with 1 μM RSL3 for 4h, and then were fixed, 
permeabilized and stained for DAPI (nuclei, blue) and 3F3 FMA (red). No 3F3 
FMA was detected in siRNA knockdown of transferrin receptor. siNT was used 
as control. White arrows indicate the absence. 
 
Then we aimed to locate 3F3 FMA within cells. We co-localized 3F3 FMA with 
Tom20 (mitochondria marker), PDI (ER marker) and GM130 (Golgi marker) using 
two secondary antibodies with different excitation and emission wavelengths. We 
found that 3F3 FMA was not in the mitochondria and the ER (Figure 4.15). 3F3 
FMA was located in the Golgi (Figure 4.16). During normal condition, most of 
them stayed in the Golgi (bright dots shown by green arrows). When ferroptosis 
initiated, they moved to plasma membrane. This translocation was confirmed by 




Figure 4.15 3F3 FMA did not target MT and ER. 
 
HT-1080 cells were incubated with 1 μM RSL3 for 4h, and then were fixed, 
permeabilized and stained with DAPI (nuclei, blue) and Tom20 (mitochondria 
marker, green) or PDI (ER marker, green) and 3F3 FMA. 3F3 FMA didn’t co-




Figure 4.16 3F3 FMA targeted the Golgi 
 
HT-1080 cells were incubated with 1 μM RSL3 for 4h, and then were fixed, 
permeabilized and stained with DAPI (nuclei, blue), GM130 (Golgi, green) and 
3F3 FMA. 3F3 FMA co-localized with the Golgi complex. White arrows indicate 
the overlap. Green arrows indicate the bright dots of 3F3 FMA in normal 
condition. 
 
We found that 3F3 FMA could still stain the plasma membrane (Figure 4.17). The 
translocation of 3F3 FMA is consistent with the activity of TfR1 in cells141. TfR1 is 
the main regulator of iron uptake in cells. After binding with iron-transferrin, it’s 
enclosed within clathrin-coated endocytic vesicles and internalized by cells. Then 
iron is released due to endosomal acidification. Apotransferrin and receptor are 
sorted by the Golgi and transported back to the cell surface. It was reasonable 
that we observed 3F3 FMA in the plasma membrane and the Golgi. But, as a 
transmembrane protein, most of the TfR1 stays in the Golgi under normal 





Figure 4.17 3F3 FMA targeted the plasma membrane 
 
HT-1080 cells were incubated with 1 μM RSL3 for 4h or 5 μM IKE for 18 h, and 
then were fixed and stained with DAPI (nuclei, blue) and 3F3 FMA (red). Without 
permeabilization, 3F3 FMA still stained cell surface clearly for cells undergoing 
ferroptosis. White arrows indicate the boundaries. 
 
4.3 Conclusion and discussion 
3F3 FMA was identified as a ferroptosis marker out of the screening of  ~4,750 
unknown target monoclonal antibodies. It accumulated on the cell surface during 
ferroptosis induced by different ferroptosis inducers and in different cancer cell 
lines. It can differentiate ferroptosis from apoptosis. Using IP-MS, we identified 
the antigen of 3F3 FMA as transferrin receptor protein 1. siRNA knockdown 
assay confirmed this identification. TfR1 is localized in the Golgi complex and 
plasma membrane.  
 
The next step was to test 3F3 FMA in other applications including flow cytometry, 
western blot and in tissue sections. Since we knew the antigen, we could order 
commercially available anti-TfR1 antibodies. We could further validate that the 
antigen is TfR1, and we could compare these anti-TfR1 antibodies with 3F3 FMA. 
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We also compared 3F3 FMA with other potential ferroptosis markers including 
anti-MDA and anti-4-HNE antibodies. 
 
4.4 Methods 
Generation of PE-induced membrane fractions 
6 L of media (1% Pen-Strep 10% FBS and 89% RPMI with L-glutamine) 
containing 400 million OCI-LY7 (DSMZ Cat# ACC-688, RRID: CVCL_1881) 
 cells/L were treated with 5 μM PE (piperazine erastin). Cells were incubated for 
19 h at 37 ˚C, then production of lipid ROS was confirmed using BODIPY-C11 by 
flow cytometry. Ferroptotic cells were pelleted in centrifuge at 1000 rpm for 10 
min at 25 ˚C. Cells were resuspended in 1 mL lysis buffer with a pan-protease 
inhibitor, lysed using a dounce homogenizer. 70 % cell lysis was confirmed by 
microscope. Pellet containing the nuclear fraction and unlysed cells was obtained 
by centrifuge at 700 x g for 10 min at 4 ˚C. Supernatant was spun at 700 x g for 
10 min at 4 ˚C. Supernatant was then transferred to a new tube and placed in 
centrifuge at 10,000 x g for 45 min at 4 ˚C. Pellet consisting of total membrane 
was resuspended in upper phase solution. Lower phase was added and mixture 
was incubated on ice for 5 min. Mixture was spun at 1000 x g for 5 min at 4 ˚C. 
Upper phase was collected and diluted with 5x volume of H2O and incubated on 
ice for 10 min. Mixture was spun at 17,000 x g for 15 min at 4 ˚C and pellet 




Purification of monoclonal antibodies and generation of 3F3-FMA 
Murine monoclonal antibody (clone FH3F3) was generated at the Fred 
Hutchinson Antibody Technology Core Facility, Seattle Washington. Briefly, 
female 20-week-old mice (various strains) were immunized with ferroptotic 
membrane fractions (see previous methods). Following a 12-week boosting 
protocol, splenocytes were isolated from four high titer mice and electrofused 
with a myeloma fusion partner generate hybridoma cells. Approximately 4,750 
hybridomas positive for IgG secretion were then identified and isolated using a 
ClonePix2 colony picker (Molecular Devices, CPII). Primary screening of the 
4,750 clones was performed by indirect flow cytometry of ferroptotic LY-7 cells (5 
μM IKE treated for 19 h at 37 ˚C, fixed with 0.01% formaldehyde in PBS for 15 
min at 22 ˚C, permeabilized in FACS buffer with 0.5% v/v Tween-20 detergent). 
Clones showing fluorescent staining ~4-fold over background levels (irrelevant 
primary antibody plus secondary antibody) were isolated for culture and frozen 
down as the “Primary Clone Archive”. Clone 3F3 was further identified within the 
Primary Clone Archive by fluorescent staining and high-content image analysis. 
Clone 3F3 was then subcloned by limiting dilution-CPII colony picking. Small 
scale antibody productions in serum free media (Gibco Hybridoma SFM) were 
carried out followed by affinity chromatography (AKTA Pure, MabSelectSuRe) to 





High-content screening and analysis 
Automation 
Plate and liquid handling was performed using a HTS platform system composed 
of a Sciclone G3 Liquid Handler from PerkinElmer (Waltham, MA, USA), a 
MultiFloTM Dispenser (Biotek Instruments, Bad Friedrichshall, Germany) and a 
CytomatTM Incubator (Thermo Fisher Scientific, Waltham, MA, USA).142 Cell 
seeding and assays were performed in black 384-well CellCarrier-384 Ultra 
Microplates (PerkinElmer, 6057300). Image acquisition and image-based 
quantification was performed using an Operetta®/ColumbusTM high-content 
imaging platform (PerkinElmer, USA).  
 
High-Content Screening assay 
For the screening with five technical replicates, HT-1080 cells were washed with 
PBS, trypsinized and resuspended in cell culture medium. The cell suspension 
(2,000 cells in 50 µl per well) was dispensed into collagen (Sigma-Aldrich, St. 
Louis, MA, USA) pre-coated 384-well plates (PerkinElmer 384-well 
CellCarrierUltraTM). 24 h after seeding, medium was exchanged to medium 
containing 0.3 µM RSL3 (1 mM stock solution) dissolved in 100% dimethyl 
sulfoxide (DMSO) or DMSO alone. 50 µl medium with 0.3 µM RSL3/DMSO was 
added per well. The cells were then incubated (37 °C; 5% CO2) for 2.5 h prior to 
fixation and antibody staining. After incubation time the medium was removed 
and cells were washed with PBS, fixed with 4% PFA for 10 min and washed 
again with PBS. After permealizing (0.5% Tween-20) for 10 min and blocking (1% 
 119 
BSA in PBS) for 2 h, cells were incubated with primary antibody selection in 
blocking solution (1:20) overnight at 4 °C. The following secondary antibody was 
applied for 1 h at room temperature: anti-mouse Alexa488 (1:500, Invitrogen). 
Cells were again washed with PBS and then stained with Hoechst 33342 and 
Phalloidin-TRITC for 1 h at r.t. in the dark and then extensively washed with PBS 
afterwards. Finally, plates were recorded using the automated Operetta® 
microscope with the 20 x high NA objective for high-resolution images 
(PerkinElmer, USA). For quantification, three images of each condition were 
recorded using three channels (Hoechst, Alexa488, TRITC). This resulted in a 
cell number of at least 100 cells of each condition in all wells. Quantification on 
cell number, cytoplasmic intensity, nucleus intensity and spot number per cell 
was performed using the Columbus Software (PerkinElmer, USA).  
 
Image analysis 
Multiparametric image analysis was performed using Columbus Software 2.8.0 
(PerkinElmer). Hoechst signal was used to detect all cell nuclei. Phalloidin-TRITC 
signal was used to determine the cytoplasmic region to the corresponding 
nucleus. Moreover, we applied a filter to remove border objects (nuclei that cross 
image borders) and cells with extremely small nuclei (dead cells). In a next step 
we have calculated the morphology and Alexa488 fluorescence intensity in each 
cell region (nucleus and cytoplasm). In addition, we performed spot detection in 
the cytoplasm and used morphology and intensity parameter for each spot to 
define “big spots”. Each spot was detected as a small region within the 
 120 
corresponding image by having a higher intensity than its surrounding area. 
Furthermore, we selected cells with three or more “big spots” in the cytoplasm 
and calculated the percentage of “positive” cells in each well. Finally, a hit was 
defined if the ratio of cytoplasmic intensity and/or the ratio of cells with more than 
3 spots was > 1 in at least 3 of 5 plates after RSL3 treatment. An illustration on 
the automated detection method using the Hoechst-, phalloidin-TRITC- and 
Alexa488 antibody- signal is presented in Figure S1. 
 
Immunofluorescence (IF)  
HT-1080 (ATCC Cat# CRL-7951, RRID:CVCL_0317), A-673, SK-BR-3, SK-LMS-
1 and Huh-7 cells were treated with 1 μM RSL3 for 4 h, 15 μM erastin for 8 h, 10 
μM IKE for 8 h, 15 μM FINO2 for 8 h, 10 μM FIN56 for 8 h, 100 μM  tBuOOH for 8 
h, 1 μM staurosporine (STS) for 6 h, 2 μM camptothecin (CPT) for 24 h, 1 μM 
RSL3 + 5 μM Fer-1 for 4 h and 10 μM IKE + 5 μM Fer-1 for 8 h on poly-lysine-
coated cover slips (Sigma Aldrich P4832) in 24-well plate. Media were taken out 
and the cells were gently washed with PBS++ (PBS with 1 mM CaCl2 and 0.5 mM 
MgCl2) twice. The cells were fixed and permeabilized by adding 200 μL/well of 4% 
paraformaldehyde (PFA) in PBS with 0.1% Triton X-100 (PBT), and incubated at 
room temperature for 18 min. The cells were then washed with PBT three times. 
Then the cells were blocked with 5% goat serum (ThermoFisher 50197Z) in PBT 
for 1 h at room temperature. The cells were incubated with purified mouse 
monoclonal antibodies (1:5 dilution), mouse mAb 3F3 FMA (1:500 dilution), 
Transferrin Receptor/CD71 Monoclonal Antibody, Clone: H68.4, Invitrogen 
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(Thermo Fisher Scientific Cat# 13-6800, RRID:AB_2533029, 1:250 dilution), 
Cd71 (D7G9X) XP® Rabbit mAb (Cell Signaling Technology Cat# 13113, 
RRID:AB_2715594, 1:100 dilution), CD71 (3B8 2A1) (Santa Cruz Biotechnology 
Cat# sc-32272, RRID:AB_627167, 1:50 dilution), Tom20 (FL-145) (Santa Cruz 
Biotechnology Cat# sc-11415, RRID:AB_2207533, 1:250 dilution), PDI antibody 
[RL90] - ER Marker (Abcam Cat# ab2792, RRID:AB_303304, 1:100 dilution), 
Gm130 (D6B1) XP® Rabbit mAb (Cell Signaling Technology Cat# 12480, 
RRID:AB_2797933, 1:3200 dilution), Anti-Malondialdehyde antibody (Abcam 
Cat# ab6463, RRID:AB_305484, 1:400 dilution), Anti-4 Hydroxynonenal antibody 
(Abcam Cat# ab46544, RRID:AB_722493, 1:50 dilution), ACSL4 Antibody (F-4) 
(Santa Cruz Biotechnology Cat# sc-365230, RRID:AB_10843105, 1:50 dilution), 
mouse mAb 1F83 (1:100 dilution), which specifically recognizes the 
malondialdehyde (MDA)-lysine adduct 4-methyl-1,4-dihydropyridine-3,5-
dicarbaldehyde (MDHDC)143, in PBT with 1% BSA and 5% goat serum overnight 
at 4 ˚C. The cells were washed with PBT for 5 min three times. The cells were 
incubated with Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary 
Antibody, Alexa Fluor 594 (Thermo Fisher Scientific Cat# A-11032, 
RRID:AB_2534091, 1:200 dilution) or Goat anti-Rabbit IgG (H+L) Highly Cross-
Adsorbed Secondary Antibody, Alexa Fluor 488 (Thermo Fisher Scientific Cat# 
A-11034, RRID:AB_2576217, 1:200 dilution) at room temperature for 1 h. The 
cells were washed with PBT for 5 min three times. ProLong Diamond antifade 
mountant with DAPI (ThermoFisher P36962) was added to stain the nucleus. All 
images were captured on a Zeiss LSM 800 confocal microscope at Plan-
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Apochromat 63x/1.40 Oil DIC objective with constant laser intensity for all 
samples. When applicable, line-scan analysis was performed on representative 




The quantification of the intensity of antibodies was analyzed using CellProfiler 
3.1.8 144 (CellProfiler Image Analysis Software, RRID:SCR_007358). Nuclei were 
firstly identified as primary objects using global minimum cross entropy strategy. 
Cytoplasm were then identified as secondary objects based on primary objects 
by propagation using global minimum cross entropy strategy. The plasma 
membranes were identified as the outermost 5 pixels of cytoplasm. Then mean 
intensities and size areas of nuclei, cytoplasm and plasma membranes were then 
measured and reported. Graphs were drawn by Prism 7.  
 
Immunoprecipitation-mass spectrometry (IP-MS)  
HT-1080 cells were seeded in DMEM (Corning 10-013-CM) and 10% Hi-FBS 
with 1% penicillin and streptomycin (PS) with 1% MEM Non-Essential Amino 
Acids Solution (100X) (Thermo Fisher Scientific 11140-076) 16 h prior to use. 
DMSO or 1 μM of RSL3 was added and incubated for 4 h. Following treatment, 
the medium was aspirated from each dish and cells were washed twice with PBS. 
Cells were lysed with 70 µl lysis buffer (RIPA buffer from ThermoFisher, cat. 
89900, 1 mM EDTA, 1 mM PMSF, 1X HaltTM protease inhibitor cocktail from 
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ThermoFisher, cat. 78430 and 1X HaltTM phosphatase inhibitor cocktail from 
ThermoFisher, cat. 78426). Unlysed cells and debris were pelleted for 15 min at 
16,000 x g at 4 ˚C. The samples were incubated with 10 μg of 3F3 FMA 
overnight at 4 ˚C with shaking. The next day, Thermo Scientific Pierce Protein 
AG Magnetic Beads (Thermo Fisher Scientific 88802) were washed with TBS 
with 0.05% Tween 20 (wash buffer) and then were incubated with 
sample/antibody mixture for 1 h with mixing. The beads were collected with a 
magnetic stand and then washed with wash buffer for three times. The beads 
were used for mass spectrometry.  
  
Trypsin digestion was performed overnight at 37 °C. Supernatants were collected 
and dried down in a speed-vac, and peptides were dissolved in a solution 
containing 3% acetonitrile and 0.1% formic acid. Peptides were desalted with 
C18 disk-packed stage-tips. Desalted peptides were injected onto an EASY-
Spray PepMap RSLC C18 50 cm x 75 μm column (Thermo Scientific), which was 
coupled to the Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific). 
Peptides were eluted with a non-linear 110 min gradient of 5-30% buffer B (0.1% 
(v/v) formic acid, 100% acetonitrile) at a flow rate of 250 nl/min. The column 
temperature was maintained at a constant 50 ˚C during all experiments. Thermo 
Scientific™ Orbitrap Fusion™ Tribrid™ mass spectrometer was used for peptide 
MS/MS analysis. Survey scans of peptide precursors were performed from 400 
to 1575 m/z at 120K FWHM resolution (at 200 m/z) with a 2 x 105 ion count target 
and a maximum injection time of 50 ms. The instrument was set to run in top 
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speed mode with 3 s cycles for the survey and the MS/MS scans. After a survey 
scan, tandem MS was performed on the most abundant precursors exhibiting a 
charge state from 2 to 6 of greater than 5 x 103 intensity by isolating them in the 
quadrupole at 1.6 Th. CID fragmentation was applied with 35% collision energy 
and resulting fragments were detected using the rapid scan rate in the ion trap. 
The AGC target for MS/MS was set to 1 x 104 and the maximum injection time 
limited to 35 ms. The dynamic exclusion was set to 45 s with a 10 ppm mass 
tolerance around the precursor and its isotopes. Monoisotopic precursor 
selection was enabled. 
 
MS data analysis 
Raw mass spectrometric data were analyzed using MaxQuant v.1.6.1.0 145  
(MaxQuant, RRID:SCR_014485) and employed Andromeda for database 
search146 at default settings with a few modifications. The default was used for 
first search tolerance and main search tolerance: 20 ppm and 6 ppm, 
respectively. MaxQuant was set up to search the reference Human proteome 
database downloaded from Uniprot. MaxQuant performed the search trypsin 
digestion with up to 2 missed cleavages. Peptide, Site and Protein FDR were all 
set to 1% with a minimum of 1 peptide needed for Identification but 2 peptides 
needed to calculate a protein level ratio. The following modifications were used 
as fixed carbamidomethyl modification of cysteine, and oxidation of methionine 
(M), Deamination for asparagine or glutamine (NQ) and acetylation on N-terminal 
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of protein were used as variable modifications. MaxQuant combined folder was 
uploaded in scaffold for data visualization. 
 
siRNA knockdown assay 
10 μM of siRNAs were combined with 250 μl of Opti-MEM serum-free media (Life 
Technologies 31985-070) in one tube. 6 μl of Lipofectamine RNAiMAX (Thermo 
Fisher Scientific 13778150) was combined with 250 μl of Opti-Mem media in 
another tube. They were equilibrated at r.t. for 5 min. Then two tubes were 
combined, transferred into 6-well plate and incubated at 37 ˚C for 20 min. 0.25 
million HT-1080 cells were then added to 6-well plate and incubated for 48 h. 
Cells were reseeded in regular media for additional 24 h. Then regular IF 









Chapter 5 Comparison of anti-TfR1 antibodies and other potential 
ferroptosis staining reagents in different applications 
5.1 Introduction 
In this chapter, we compared the 3F3 FMA with three other TfR1 antibodies 
(TfR1 3B8 2A1, TfR1 H68.4 and TfR1 D7G9X), as well as MDA, 4-HNE and 
ACSL4 antibodies, to assess their scope of applications. We found that TfR1 3B8, 
TfR1 H68.4, MDA 1F83 and 4-HNE ab46545 could detect ferroptotic cells by 
immunofluorescence. Flow cytometry was sensitive enough to detect the 
difference between RSL3-treated and DMSO-treated groups for all tested 
antibodies. Western blotting is not a good application for all TfR1 antibodies. 
TfR1 3B8 2A1 and MDA 1F83 antibodies showed robust results in mouse 
xenograft human tumor tissue sections. We proposed to use a combination of 




5.2.1 Comparison of anti-TfR1 antibodies and other potential ferroptosis 
staining reagents in immunofluorescence 
In addition to 3F3 FMA, we purchased three other TfR1 antibodies. One goal was 
to test if they had similar staining pattern changes with 3F3 FMA, thereby further 
validating the antigen. The other goal was to compare these TfR1 antibodies to 
see if one had advantages over the others. To find the most specific and reliable 
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ferroptosis marker, we also compared these TfR1 antibodies with MDA, 4-HNE 
and ACSL4 antibodies. RSL3 was used to induce ferroptosis. We saw an 
increase of membrane intensities for TfR1 3B8 2A1 and TfR1 H68.4 (Figure 5.1) 
but not for TfR1 D7G9X (Figure 5.2). This is reasonable because they have 
different target residues. Both TfR1 3B8 2A1 and TfR1 H68.4 target ectodomains 
whereas TfR1 D7G9X targets cytoplasmic domain (residues 3-28). There’s an 
increase of ectodomains of TfR1 as well as translocation from cytoplasm to the 
cell surface during ferroptosis. 3F3 FMA might also target ectodomains based on 
the staining pattern. 
 
Figure 5.1 3F3 FMA, TfR1 3B8 2A1, and TfR1 H68.4 antibodies could be used 
as ferroptosis marker by IF 
 
HT-1080 cells were incubated with 1 μM RSL3 for 4h, and then were fixed, 
permeabilized and stained with DAPI (nuclei, blue), 3F3 FMA, TfR1 3B8 2A1 and 
TfR1 H68.4 antibodies (red). White arrows indicate the differences. Quantification 
of membrane intensities of TfR1 antibodies was shown in the bottom (3F3 FMA, 
n= 107 and 96; TfR1 3B8 2A1, n = 32 and 9; TfR1 H68.4, n = 22 and 13). **** 
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indicated p value ≤ 0.0001 (two-tailed t-test). Data plotted are mean ± s.e.m. 
Each dot represents one cell. 
 
 
Figure 5.2 TfR1 D7G9X, MDA ab6463 and ACSL4 sc-365230 antibodies cannot 
be used as ferroptosis markers 
 
HT-1080 cells were incubated with 1 μM RSL3 for 4 h, and then were fixed, 
permeabilized and stained with DAPI (nuclei, blue), TfR1 D7G9X (green), MDA 
ab6463 (green) and ACSL4 sc-365230 antibodies (red). Quantification of 
membrane intensities of the antibodies was shown in the bottom (TfR1 D7G9X, n 
= 23 and 6; MDA ab6463, n = 49 and 27; ACSL4 sc-365230, n = 69 and 41. * 
indicated p value ≤ 0.05 and ns indicated p value > 0.05 (two-tailed t-test). Data 
plotted are mean ± s.e.m. Each dot represents one cell.  
 
Next, we compared other potential ferroptosis staining reagents – MDA 1F83, 
MDA ab6463, 4-HNE ab46545 and ACSL4 sc-365230 antibodies. We found that 
MDA 1F83 and 4-HNE ab46545 worked in RSL3-induced ferroptosis for HT-1080 
cells as well (Figure 5.3). We saw an increase of intensities in cell membrane. 
However, MDA ab6463 antibody and ACSL4 sc-365230 antibody did not work 
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(Figure 5.2). In summary, 3F3 FMA, TfR1 antibodies targeting ectodomains, 
MDA 1F83 antibody and 4-HNE ab46545 antibody can be used as ferroptosis 
markers by IF in cell culture. 
 
Figure 5.3 MDA 1F83 and 4-HNE antibodies could be used as ferroptosis marker 
by IF 
 
HT-1080 cells were incubated with 1 μM RSL3 for 4 h, and then were fixed, 
permeabilized and stained with DAPI (nuclei, blue), MDA 1F83 antibody (red) 
and 4-HNE ab46545 antibodies (green). White arrows indicated the differences. 
Quantification of membrane intensities of the antibodies was shown in the bottom 
(MDA 1F83, n = 35 and 73; 4-HNE ab46545, n = 33 and 26). **** indicated p 
value ≤ 0.0001 (two-tailed t-test). Data plotted are mean ± s.e.m. Each dot 
represents one cell. 
 
We then tested all working antibodies in STS-induced apoptosis to see if these 
antibodies could differentiate ferroptosis from apoptosis. Cleaved caspase-3 
antibody was used to show the initiation of apoptosis. Unlike ferroptosis, we 
found that TfR1 didn’t accumulate on the cell surface in apoptosis. Consistent 
with the formation of apoptotic bodies, TfR1 was detected outside of the intact 
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cells (Figure 5.4). Quantification did not show an increase in intensities of TfR1 
antibodies in cell membrane but rather a slight decrease. Neither membranous 
MDA nor 4-HNE increased during apoptosis as well, indicating that both could 
differentiate ferroptosis from apoptosis.  
 
Figure 5.4 3F3 FMA, TfR1 3B8 2A1, TfR1 H68.4, MDA 1F83 and 4-HNE 
antibodies could differentiate ferroptosis from STS-induced apoptosis 
 
HT-1080 cells were incubated with 1 μM STS for 6 h, and then were fixed, 
permeabilized and stained with DAPI (nuclei, blue), 3F3 FMA (red), TfR1 3B8 
2A1 (red), TfR1 H68.4 (red), MDA 1F83 (red) and 4-HNE ab46545 antibodies 
(green). White arrows indicated the stain out of intact cells. Quantification of 
membrane intensities of the antibodies was shown in the bottom (3F3 FMA, n = 
71 and 53; TfR1 3B8 2A1, n = 103 and 63; TfR1 H68.4, n = 93 and 80; MDA 
1F83, n = 81 and 71; 4-HNE ab46545, n = 56 and 69). ns indicated p value > 
0.05 (two-tailed t-test). Data plotted are mean ± s.e.m. Each dot represents one 
cell. 
 
We also tested TfR1 3B8 2A1, TfR1 H68.4, MDA 1F83, and 4-HNE ab46545 
antibodies in camptothecin-induced apoptosis antibodies in camptothecin-
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induced apoptosis; cleaved PARP antibody was used to show initiation of 
apoptosis. We found that, as with STS-induced apoptosis, TfR1 did not 
accumulate on the cell surface; there was rather a decrease in membrane 
intensity (Figure 5.5). The membrane intensity of MDA 1F83 and 4-HNE ab46545 
antibodies didn’t change apparently in camptothecin-treated cells. This indicates 
that TfR1 antibodies may be overall more effective in differentiating ferroptosis 
from apoptosis. 
 
Figure 5.5 3F3 FMA, TfR1 3B8 2A1, TfR1 H68.4, MDA 1F83 and 4-HNE 
antibodies could differentiate ferroptosis from CPT-induced apoptosis 
 
HT-1080 cells were incubated with 2 μM camptothecin for 24 h, and then were 
fixed, permeabilized and stained with DAPI (nuclei, blue), 3F3 FMA (red), TfR1 
3B8 2A1 (red), TfR1 H68.4 (red), MDA 1F83 (red) and 4-HNE ab46545 
antibodies (green). Quantification of membrane intensities of the antibodies was 
shown in the bottom (3F3 FMA, n = 166 and 91; TfR1 3B8 2A1, n = 164 and 116; 
TfR1 H68.4, n = 186 and 112; MDA 1F83, n = 109 and 119; 4-HNE ab46545, n = 
122 and 74). Data plotted are mean ± s.e.m. Each dot represents one cell. 
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5.2.2 Comparison of anti-TfR1 antibodies and other potential ferroptosis 
staining reagents in flow cytometry and western blot 
To explore the scope of applications for the antibodies, TfR1, MDA and 4-HNE 
antibodies were tested using flow cytometry and western blot, in addition to IF. 
We found that all antibodies showed increased intensities in RSL3-treated HT-
1080 cells (Figure 5.6). Compared to C11-BODIPY which is a sensor of lipid 
peroxidation, TfR1 H68.4, MDA ab6463 and 4-HNE ab46545 antibodies showed 
more distinct differences between DMSO and RSL3-treated cells.  
 
Figure 5.6 TfR1, MDA and 4-HNE antibodies worked in flow cytometry 
 
HT-1080 cells were treated with DMSO or 1 μM RSL3 for 4 h. Cells were then 
harvested and stained with 1st and 2nd antibodies or C11-BODIPY without 
permeabilization. Around 15,000 cells were recorded and gated. RSL3-treated 
cells had increased intensities of 3F3 FMA, TfR1 3B8 2A1, TfR1 H68.4, MDA 
1F83, MDA ab6463, 4-HNE ab46545. C11-BODIPY, a probe for lipid 
peroxidation was used as a metric. 
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However, in western blot, no bands were detected by 3F3 FMA and TfR1 3B8 
2A1 antibodies, indicating that neither could recognize denatured TfR1 proteins 
(Figure 5.7). Though TfR1 H68.4 and TfR1 D7G9X could recognize denatured 
TfR1, there were not a protein level difference (Figure 5.7). This result implies 
that the total cellular amount of TfR1 might not change during ferroptosis. The 
change might be the translocation to the cell surface.  
 
Figure 5.7 TfR1 antibodies didn’t work in western blot 
 
HT-1080 cells were treated with DMSO or 1 μM RSL3 for 4 h. Cells were 
collected, lysed, stained with 1st and 2nd antibodies and detected using western 
blot. No bands were detected with 3F3 FMA and TfR1 3B8 2A1. No difference of 
protein level between DMSO and RSL3 group were detected with TfR1 H68.4 
and TfR1 D7G9X. 
 
5.2.3 Comparison of anti-TfR1 antibodies and other potential ferroptosis 
staining reagents in mouse xenograft tumor tissue sections 
Finally, we tested 3F3 FMA together with other TfR1 antibodies as well as MDA 
and 4-HNE antibodies in mouse xenograft tumor tissue samples. The preparation 
of human B cell lymphoma xenograft tissue samples was described previously 126. 
6-week-old NCG mice were injected with 10 million SU-DHL-6 cells 
subcutaneously. The mice were treated after the tumor size reached 100 mm3. 
Mice were separated randomly into treatment groups and dosed with vehicle and 
3F3 FMA TfR1 3B8 2A1 TfR1 H68.4 TfR1 D7G9X
DMSO RSL3 DMSO RSL3 DMSO RSL3 DMSO RSL3
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40 mg/kg IKE once daily by IP for 14 days. 3 h after the final dosage, mice were 
euthanized with CO2 and tumor tissue was dissected, frozen, fixed and cut to 
make slides (Figure 5.8). We found that TfR1 3B8 2A1, TfR1 H68.4 and MDA 
1F83 showed significant increase of intensities in IKE-treated samples; however, 
3F3 FMA did not detect (Figure 5.9). MDA ab6463 and 4-HNE ab46545 showed 
increased intensities in IKE-treated samples as well but to a lesser extent (Figure 
5.9).  
 
Figure 5.8 An illustration of the preparation of the B cell lymphoma mouse 
xenograft tumor and IKE dosage 
 
 
Figure 5.9 Comparison of TfR1 antibodies and other potential ferroptosis staining 




Tumor size 100 mm3






B cell lymphoma tumor tissues were fixed in 4% PFA for 24 h, perfused in 30% 
sucrose for 24 h, and stained with 1st and 2nd antibodies. TfR1 3B8 2A1, TfR1 
H68.4 and MDA 1F83 showed significant difference of intensities between 
vehicle and IKE group. 3F3 FMA showed no difference. MDA ab6463 and 4-HNE 
ab46545 showed slight difference. Quantification of overall intensity of the 
antibodies was shown in the bottom (n=7). **** indicated p value ≤ 0.0001, *** 
indicated p value ≤ 0.001, ** indicated p value ≤ 0.01, * indicated p value ≤ 0.05, 
and ns indicated p value > 0.05 (two-tailed t-test). Data plotted are mean ± s.e.m. 
Each dot represents one cell. 
 
HCC (Hepatocellular carcinoma) mouse xenograft tissue samples were obtained 
by injecting 6-week-old NCG mice with 5 million Huh7 cells. After three weeks, 
mice were dosed with vehicle and 50 mg/kg IKE once daily by IP for 2 days. 3 h 
after the final dosage, mice were euthanized with CO2 and tumor tissue was 
dissected, frozen, fixed and cut to make slides (Figure 5.10). Only 3F3 FMA, 
TfR1 3B8 2A1 and MDA 1F83 antibodies showed increased intensities in IKE-
treated samples (Figure 5.11). Overall, TfR1 3B8 2A1 and MDA 1F83 worked 
consistently in both samples and was recommended as a robust ferroptosis 
marker in frozen tissue sample.  
 
Figure 5.10 An illustration of the preparation of the HCC mouse xenograft tumor 









Timeline24 h 48 h
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Figure 5.11 Comparison of TfR1 antibodies and other potential ferroptosis 
staining reagents in HCC mouse xenograft tumor tissue samples 
 
HCC tumor tissues were fixed in 4% PFA for 24 h, perfused in 30% sucrose for 
24 h, and stained with 1st and 2nd antibodies. 3F3 FMA, TfR1 3B8 2A1 and MDA 
1F83 showed apparent difference of intensities between vehicle and IKE group, 
while other antibodies didn’t. Quantification of overall intensity of the antibodies 
was shown in the bottom (n=7). **** indicated p value ≤ 0.0001, ** indicated p 
value ≤ 0.01, and ns indicated p value > 0.05 (two-tailed t-test). Data plotted are 
mean ± s.e.m. Each dot represents one cell. 
 
We also tested 3F3 FMA in human Huntington’s disease (HD) brain tissues. 
However, the expression of TfR1 in brain tissue was low. We did not detect any 
differences between the control group and HD group (Figure 5.12). We also 
tested 3F3 FMA in mouse liver frozen tissue samples and mouse glioblastoma 
(GBM) paraffin-embedded samples. 3F3 FMA was able to recognize mouse TfR1 
protein as well (Figure 5.13).  
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Figure 5.12 3F3 FMA staining in human Huntington’s disease 
 
Human HD and control brain tissues were fixed in 4% PFA for 24 h, perfused in 
30% sucrose for 24 h, and stained with DAPI (nuclei, blue) and 3F3 FMA (red). 




Figure 5.13 3F3 FMA staining in mouse tissue sections 
 
Mouse liver tissues and mouse GBM tissues were fixed and stained with DAPI 
(nuclei, blue) and 3F3 FMA (red). 3F3 FMA was able to recognize mouse TfR1. 
 
5.3 Conclusion 
We assessed 3F3 FMA together with three commercially available TfR1 
antibodies and four potential ferroptosis staining reagents in different assays (IF, 
flow cytometry, and tissue sections). A summary of their applications is shown in 
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Table 5.1. To note, the TfR1 3B8 2A1 and MDA 1F83 antibodies perform best. 
They yielded reliable results in mouse xenograft tumor tissue samples as well as 
IF and flow cytometry. We proposed to use a combination of TfR1 3B8 2A1 and 
MDA 1F83 antibodies as ferroptosis markers to stain human tissue sections, 
which will aid the research of the role of ferroptosis in various human disease 
and pathologies. 
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Table 5.1 A summary of different applications for all antibodies 
 
Eight antibodies were evaluated in IF, flow cytometry, WB (western blot) and two 
mouse xenograft tumor tissue samples using immunofluorescence. TfR1 3B8 





Flow cytometry and analysis 
Cells were resuspended in 500 mL HBSS containing 2 μM C11-BODIPY 
(BODIPY 581/591 C11) (Thermo Fisher Scientific, D3861) and incubated at 37 
˚C for 15 min. Cells were pelleted and resuspended in HBSS strained through a 
35 μm cell strainer (Fisher Scientific 08-771-23). Fluorescence intensity was 
measured on the FL1 channel with gating to record live cells only (gate 
constructed from DMSO treatment group). A minimum of 10,000 cells were 
analyzed per condition. Analysis was performed using FlowJo software. 
 
HT-1080 cells were treated with DMSO or 1 μM RSL3 for 4 h. The cells were 
harvested by 0.25% Trypsin-EDTA (1X) (Invitrogen 25200-114) and washed with 
HBSS once. The cells were resuspended in 5% goat serum (ThermoFisher 
50197Z) for 30 min on ice. The cells were incubated with mAb 3F3 FMA (1:500 
dilution), Transferrin Receptor/CD71 Monoclonal Antibody, Clone: H68.4, 
Invitrogen (Thermo Fisher Scientific Cat# 13-6800, RRID:AB_2533029, 1:250 
dilution), CD71 (3B8 2A1) (Santa Cruz Biotechnology Cat# sc-32272, 
RRID:AB_627167, 1:50 dilution), Anti-Malondialdehyde antibody (Abcam Cat# 
ab6463, RRID:AB_305484, 1:400 dilution), Anti-4 Hydroxynonenal antibody 
(Abcam Cat# ab46544, RRID:AB_722493, 1:50 dilution), mand ouse mAb 1F83 
(1:100 dilution), which specifically recognizes the malondialdehyde (MDA)-lysine 
adduct 4-methyl-1,4-dihydropyridine-3,5-dicarbaldehyde (MDHDC)143 for 1 h on 
ice. The cells were washed with HBSS for 5 min three times by centrifugation. 
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The cells were incubated with Goat anti-Mouse IgG (H+L) Secondary Antibody, 
Alexa Fluor® 488 conjugate (Thermo Fisher Scientific Cat# A-11001, 
RRID:AB_2534069, 1:200 dilution)  or Goat anti-Rabbit IgG (H+L) Highly Cross-
Adsorbed Secondary Antibody, Alexa Fluor 488 (Thermo Fisher Scientific Cat# 
A-11034, RRID:AB_2576217, 1:200 dilution) for 30 min on ice. The cells were 
washed with HBSS twice by centrifugation, then resuspended in HBSS strained 
through a 35 μm cell strainer (Fisher Scientific 08-771-23). Fluorescence 
intensity was measured on the FL1 channel with gating to record live cells only 
(gate constructed from DMSO treatment group). A minimum of 10,000 cells were 




Lymphoma mouse xenograft tumor tissues were got from Dr. Yan Zhang, HCC 
mouse xenograft tumor tissues were got from Dr. Presha Rajbhandari. Tumor 
tissues were fixed in 4% paraformaldehyde (PFA) for 24 h at 4 ˚C followed by 
washing with PBS three times. The tissues were perfused in 30% sucrose for 24 
h at 4 ˚C for cryo-protection. The samples were embedded in OCT cryostat 
sectioning medium, and then moved directly into a cryostat. After equilibration of 
temperature, frozen tumor tissues were cut into 5 μm thick sections. Tissue 
sections were mounted on to poly-L-lysine coated slides by placing the cold 
sections onto warm slides. Slides were stored at -80 ˚C until staining. For 
staining, slides were warmed to room temperature followed by washing with PBS 
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twice. A hydrophobic barrier pen was used to draw a circle on each slide. The 
slides were permeabilized with PBS with 0.4% Triton X-100 (PBT) twice before 
non-specific-binding blocking by incubating the sections with 10% goat serum 
(ThermoFisher 50197Z) for 30 min at room temperature. The sections were 
separately incubated with mouse mAb 3F3 FMA (1:500 dilution), Transferrin 
Receptor/CD71 Monoclonal Antibody, Clone: H68.4, Invitrogen (Thermo Fisher 
Scientific Cat# 13-6800, RRID:AB_2533029, 1:250 dilution), CD71 (3B8 2A1) 
(Santa Cruz Biotechnology Cat# sc-32272, RRID:AB_627167, 1:50 dilution), 
Anti-Malondialdehyde antibody (Abcam Cat# ab6463, RRID:AB_305484, 1:400 
dilution), Anti-4 Hydroxynonenal antibody (Abcam Cat# ab46544, 
RRID:AB_722493, 1:50 dilution), mand ouse mAb 1F83 (1:100 dilution), which 
specifically recognizes the malondialdehyde (MDA)-lysine adduct 4-methyl-1,4-
dihydropyridine-3,5-dicarbaldehyde (MDHDC)143 overnight at 4 ˚C in humidified 
chambers. Sections were washed with PBT for three times before incubating with 
Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa 
Fluor 594 (Thermo Fisher Scientific Cat# A-11032, RRID:AB_2534091, 1:1000 
dilution) or Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary 
Antibody, Alexa Fluor 488 (Thermo Fisher Scientific Cat# A-11034, 
RRID:AB_2576217, 1:1000 dilution) at room temperature for 1 h. Slides were 
then washed twice with PBT three times. ProLong Diamond antifade mountant 
with DAPI (ThermoFisher P36962) was added onto slides, which were then 
covered with the coverslips, sealed by clear fingernail polish and observed under 
confocal microscopy. All images were captured on a Zeiss LSM 800 confocal 
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microscope at Plan-Apochromat 63x/1.40 Oil DIC objective with constant laser 
intensity for all analyzed samples. The intensity above threshold of the 
fluorescent signal of the bound antibodies was analyzed using NIH ImageJ 
software (ImageJ, RRID:SCR_003070). Data were expressed as fold change 
comparing with the vehicle. 
 
Western blot 
HT-1080 cells were seeded in DMEM (Corning 10-013-CM) and 10% Hi-FBS 
with 1% penicillin and streptomycin (PS) with 1% MEM Non-Essential Amino 
Acids Solution (100X) (Thermo Fisher Scientific 11140-076) 16 h prior to use. 
DMSO or 1 μM of RSL3 was added and incubated for 4 h. Following treatment, 
the medium was aspirated from each dish and cells were washed twice with PBS. 
Cells were lysed with 70 µl lysis buffer (RIPA buffer from ThermoFisher, cat. 
89900, 1 mM EDTA, 1 mM PMSF, 1X HaltTM protease inhibitor cocktail from 
ThermoFisher, cat. 78430 and 1X HaltTM phosphatase inhibitor cocktail from 
ThermoFisher, cat. 78426). Unlysed cells and debris were pelleted for 15 min at 
16,000 x g at 4 ˚C. Samples were separated using SDS-PAGE and transferred to 
a polyvinylidene difluoride membrane. Transfer was performed using the iBlot2 
system (Invitrogen). Membranes were treated with Li-COR Odyssey blocking 
buffer for at least 1 h at r.t., then incubated with mouse mAb 3F3 FMA (1:500 
dilution), Transferrin Receptor/CD71 Monoclonal Antibody, Clone: H68.4, 
Invitrogen (Thermo Fisher Scientific Cat# 13-6800, RRID:AB_2533029, 1:250 
dilution), Cd71 (D7G9X) XP® Rabbit mAb (Cell Signaling Technology Cat# 
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13113, RRID:AB_2715594, 1:100 dilution), CD71 (3B8 2A1) (Santa Cruz 
Biotechnology Cat# sc-32272, RRID:AB_627167, 1:50 dilution) in a 1:1 solution 
of PBS-T (PBS with 0.1% Tween 20) and Li-COR odyssey blocking buffer 
overnight at 4 ˚C. Following three 5 min washes in PBS-T, the membrane was 
incubated with secondary antibodies, goat anti-rabbit or goat anti-mouse IgG 
antibody conjugated to an IRdye at 800CW (LI-COR Biosciences Cat# 926-
32211, RRID:AB_621843, 1:3000 dilution)  and Alexa Fluor 680 goat anti-mouse 
IgG (H+L) (Thermo Fisher Scientific Cat# A-21058, RRID:AB_2535724, 1:3000 
dilution) in a 1:1 solution of PBS-T and Li-COR Odyssey blocking buffer for 1 h at 
r.t. Following three 5 min washes in PBS-T, the membrane was scanned using 







Chapter 6 Conclusions and perspectives 
6.1 Drug development for oncogenic K-RasG12D 
6.1.1 Significance 
We discovered a potential allosteric binding site on oncogenic K-RasG12D for the 
first time. We termed it the P110 site because it is close to proline110. The P110 
site includes residues Arg97, Asp105, Ser106, Glu107, Asp108, Val109, Pro110, 
Met111, Tyr 137, Gly138, ILE139, Glu162, Lys165, and His166. KAL-21404358 
was designed to bind to the P110 site and was identified using a tiered set of 
computational and biochemical assays. The binding affinity (KD) of KAL-
21404358 to K-RasG12D is around 100 μM. The binding of KAL-21404358 causes 
conformational changes of residues in the Switch I and II region and disrupts the 
interactions with B-Raf. KAL-21404358 is able to interrupt K-RasG12D downstream 
signaling pathways. 
 
The development of small-molecule inhibitors of K-Ras is of broad and current 
interest. Most of the compounds are targeting the primary active sites (also 
known as orthosteric sites) including P loop (residue 10-17), Switch I (residue 30-
40) and Switch II (residue 60-75). Few compounds are designed for the allosteric 
lobe where the P110 site resides in. Drugs fitting into the primary active sites are 
straightforward and effective as most on-market drugs belong to this category. 
However, they have several disadvantages. The first disadvantage is off-target 
activity. The primary active sites are the most evolutionarily conserved, as they 
maintain the basic function of the enzyme or receptor. So, it is common to share 
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similar active sites among several proteins belonging to the same family. Thus, 
orthosteric inhibitors may have broader binding targets then allosteric inhibitors. 
The second disadvantage is the rigidity. The binding of an orthosteric inhibitor to 
the primary active site usually yields a binary all-or-nothing effect. This complete 
inhibition lacks flexibility and adjustability, which might be important for refined 
biological mechanisms. Another disadvantage is the lack of co-operativity. 
Allosteric inhibitors can be used in addition to the orthosteric inhibitors at the 
same time, thereby boosting the overall inhibition or activation effects. Due to 
these disadvantages of orthosteric inhibitors and lack of allosteric inhibitors for K-
Ras proteins, the discovery is exciting and significant.  
 
6.1.2 Future directions 
Though the discovery of the allosteric small-molecule inhibitor KAL-21404358 is 
exciting, there are several concerns. Firstly, the binding affinity of KAL-21404358 
is relatively low compared to other potential oncogenic Ras inhibitors. This 
means that its ability to interrupt Ras-effector interactions and the following 
signaling pathway is also low. Therefore, to take further steps, the optimization 
for higher efficacy and specificity is highly needed. We modified several 
functional groups on KAL-21404358 and conducted a structure-activity 
relationship (SAR) analysis; however, we did not find any better analogs which 
have higher efficacy than KAL-21404358. Secondly, we don’t have direct 
evidence that KAL-21404358 binds to the P110 site. We constructed four 
binding-deficient mutants around the P110 site and didn’t detect any binding 
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events by MST, which is a strong argument. In the HSQC NMR experiment, we 
did see chemical shifts of residues in the Switch I and II region (the allosteric 
effect), but we didn’t detect any shifts of the residues around the P110 site. It is 
reasonable because the interactions between KAL-21404358 and the P110 site 
are through side chains of amino acids which cannot be detected by HSQC NMR 
experiments. To provide stronger evidence of the binding site and a powerful 
guide for lead optimization, a high-resolution structure is highly needed. This is 
one of the most important future directions for this project. 
 
A binding model of KAL-21404358 was proposed in chapter three. We 
hypothesize that KAL-21404358 binds to the GTP-bound K-RasG12D state 1 
(inactive) and thus shifts the protein equilibrium from state 2 (active) toward state 
1. KAL-21404358 also binds to and stabilizes K-RasG12D in the inactive GDP-
bound state by reducing its probability to nucleotide exchange, thus decreasing 
the amount of GTP-bound K-RasG12D (active). However, this model was not 
validated by experiments. Experiments that can differentiate state 1 and state 2 
of GTP-bound K-RasG12D will be helpful for better model explanation.  
 
We tested that KAL-21404358 was able to interrupt the downstream effector 
interactions and signaling pathways; however, we didn’t have a chance to test if 
KAL-21404358 could disrupt upstream interactions i.e., GEF and GAP 
interactions. The binding of KAL-21404358 might also slow the rate of nucleotide 
exchange by GEF or accelerate the hydrolysis of GTP by GAP. Fluorescent 
 147 
BODIPY-GTP together with incubation with either GEF or GAP is a powerful tool 
to test this hypothesis. 
   
6.2 Identification of ferroptosis biomarkers 
6.2.1 Significance 
We found for the first time that anti-TfR1 antibodies could be used as ferroptosis 
staining markers. A combination of TfR1 3B8 2A1 and MDA 1F83 antibodies was 
proposed to be used to stain ferroptotic cells in human tissue sections. Why is 
this discovery significant? I summarize three reasons. Ferroptosis is a recently 
established regulated cell death process. However, normal physiological function 
for ferroptosis has not been identified. To study the role of ferroptosis in 
physiological and pathological functions, conventional ferroptosis markers 
including the increase of lipid peroxidation, increase of redox active iron and 
impair of enzymatic activity of GPX4, are not applicable. Ferroptosis specific 
antibody staining is a more direct and straightforward way to detect cells or 
tissues undergoing ferroptosis. Parkinson’s disease (PD) for example has been 
found to involve several molecular events, including the increase of redox active 
iron, GSH depletion, and lipid peroxidation, that also have been identified as 
hallmarks of ferroptosis147. Iron chelators and ferrostatin-1, typical ferroptosis 
inhibitors, have been found to ameliorate motor symptoms in multiple animal 
models of PD148, 149. The use of ferroptosis staining markers in PD tissue 
samples will be a powerful tool for research on the relationship between 
ferroptosis and PD.  
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Secondly, a ferroptosis specific staining antibody can be used as a measure in 
any other study related to ferroptosis. Recently, our lab found that the induction 
of ferroptosis can synergize with radiation therapy in tumor suppression 
treatment. The mechanism of ferroptosis in radiation and tumor suppression 
remains appealing but elusive. The use of a ferroptosis marker to detect if 
ferroptosis occurs in human patients pre- and post-radiation treatment is of great 
significance. Another potential use of a ferroptosis marker is to test if ferroptosis 
inducers can be used in mouse studies. Considering ferroptosis’s role in tumor 
suppression, we are interested in the application of ferroptosis inducers to clinical 
trials as anti-tumor drugs. Conducting pre-clinical research in mouse xenograft 
models is a fundamental step before that. Ferroptosis markers would be useful in 
such a study to identify the occurrence of ferroptosis in mouse xenograft tumor 
sections.  
 
Thirdly, the identification of TfR1 is of equal significance. TfR1 is the main 
regulator of iron uptake in cells. After binding with iron-transferrin, it is enclosed 
within clathrin-coated endocytic vesicles and internalized by cells. Iron is then 
released due to endosomal acidification. Apotransferrin and receptor are sorted 
by the Golgi and transported back to the cell surface. Our observation of the 
movement of TfR1 is consistent with the activities of TfR1 within cells. This 
observation not only confirmed the antigen identification, but also opened up a 
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new future direction to study the role of TfR1 in ferroptosis, discussed in the 
following section.  
 
6.2.2 Future directions 
Anti-TfR1 antibodies are able to differentiate ferroptosis from apoptosis. However, 
other non-apoptotic regulated cell death (RCD) including necroptosis and 
pyroptosis have not been tested. Necroptosis is initiated by the activation of 
death receptor tumor necrosis factor receptor 1 (TNFR1) followed by the 
phosphorylation of RIPK1, RIPK3, and MLKL150. Necroptosis shares several 
regulating components with apoptosis, including caspase 8, RIPK1, and TNFR1. 
Pyroptosis is driven by the activation of inflammasome followed by the activation 
of caspase 1, caspase 11 (mouse) or caspase 4 and 5 (human) and gasdermin D 
(GSDMD)150. Shared regulating components among necroptosis, pyroptosis and 
ferroptosis have not been identified. It is worth testing anti-TfR1 antibody staining 
patterns in necroptosis and pyroptosis. 
 
In addition to TfR1’s use as a ferroptosis marker, we are also interested in why 
TfR1 accumulation on the cell surface occurs during ferroptosis. One hypothesis 
is that the internalization machinery is disrupted in the ferroptotic context. To test 
this hypothesis, we choose Epidermal Growth Factor Receptor (EGFR) because 
it uses the same clathrin-mediated endocytosis as TfR1 and is internalized in the 
presence of EGF only. However, EGFR was still internalized in the presence of 
EGF during ferroptosis, indicating that clathrin-mediated endocytosis wasn’t 
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affected (Figure 6.1). Therefore, we hypothesize that recruitment of TfR1 to the 
plasma membrane during ferroptosis is more likely related to iron metabolism. 
This might occur through a positive feedback cycle between iron uptake and 
ferroptotic death. However, this hypothesis needs more supporting evidence.  
 
Figure 6.1 EGFR was internalized during ferroptosis 
 
HT-1080 cells were incubated with 1 μM RSL3 in serum-free medium for 4 h 
(ferroptosis induction and serum starvation), and were incubated with 25 ng/mL 
EGF for 40 min. Cells were then fixed, permeabilized and stained with DAPI 
(nuclei, blue) and EGFR (red). EGFR was internalized in the presence of EGF 
during ferroptosis, indicating that clathrin-mediated endocytosis wasn’t affected in 
ferroptosis. 
 
A further direction is to study the role of TfR1 in ferroptosis. It was reported that 
cells with knockdown of TfR1 became more resistant to erastin-induced 
ferroptosis114 and TfR RNAi significantly inhibited serum-dependent necrosis, 
which turned out to be ferroptosis83. These results suggest that TfR1 plays a key 
role in the initiation of ferroptosis. However, research on the role of TfR1 in 
ferroptosis is insufficient. The evaluation of ferroptosis-related metabolites such 
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as squalene synthase, coenzyme Q10, GPX4 and glutathione might help us 
understand the role of TfR1 better. 
 
Two subtypes of TfRs have been identified: TfR1 and TfR2. TfR1 is ubiquitously 
expressed at low levels in most normal human tissues whereas TfR2 is 
predominantly expressed in hepatocytes and erythroid precursor151. In normal 
human tissues, it might be hard to use anti-TfR1 antibodies as ferroptosis 
markers due to the low expression of the receptor. However, TfR1 is abundantly 
expressed in various cancers152. Considering the anti-tumor activity of ferroptosis, 
anti-TfR1 antibodies can be used as a good ferroptosis marker in staining tumor 
tissues.  
 
Beyond the abnormal expression, TfR1 is actively involved in the progression of 
several kinds of cancers including brain cancer, breast cancer, colon cancer, liver 
cancer, etc., rendering TfR1 a valuable pharmaceutical target for treating 
cancers153. The increased need of iron uptake leads to the high expression of 
TfR1 because iron is required for tumor cell proliferation154. On the other hand, 
the upregulation of iron uptake by TfR1 also refills the labile redox active iron 
pool, which is needed for ferroptosis. Therefore, how iron metabolism is 
regulated between tumor progression and ferroptotic tumor suppression still 
remains elusive. More research is needed to illustrate the relationship between 
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